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SUMMARY 
 
 Chromosomal rearrangements leading mostly to fusion oncoproteins of the Mixed 
Lineage Leukemia (MLL) gene occur in about 10% of all patients with acute leukemia and 
are often associated with poor clinical outcome, emphasizing the need for new treatment 
modalities. The MLL protein forms a ternary complex with the lens epithelium-derived 
growth factor (LEDGF/p75 also known as PSIP1) and another protein MENIN. Previous 
work has shown that LEDGF/p75 contributes to the association of the MLL multi-protein 
complex to chromatin. In addition, LEDGF/p75 is known for acting as a tether of the 
human immunodeficiency virus 1 (HIV-1) pre-integration complex to chromatin, and 
previous works has demonstrated that expression of the C-terminal fragment fused to 
eGFP (eGFP-LEDGF/p75325-530) impaired HIV-1 replication. Here, we explored this 
strategy to selectively interfere with the leukemogenic activity of MLL-fusion proteins. We 
found that expression of the LEDGF/p75325-530 fragment impaired the clonogenic growth of 
MLL-fusion gene transformed human and mouse leukemic cell lines, without affecting the 
growth of immortalized control cells, or normal lineage marker-depleted murine bone 
marrow cells. Expression of LEDGF/p75325-530 was associated with downregulation of the 
known MLL target Hoxa9 and associated with impaired cell cycle progression. Structure-
function analysis revealed two small eGFP fused LEDGF/p75 peptide-sized fragments, 
LEDGF/p75424-435 and LEDGF/p75375-386 were able to phenocopy these effects. 
LEDGF/p75325-530 and the smaller active peptides were all able to disrupt the LEDGF/p75-
MLL interaction. Expression of LEDGF/p75325-530 or the LEDGF/p75375-386 fragment 
increased the latency period to disease development in vivo in a mouse bone marrow 
transplant model of MLL-AF9 induced acute myeloid leukemia (AML). From these studies 
we concluded that small peptides disrupting the LEDGF/p75-MLL interface have selective 
anti-leukemic activity providing a direct rationale for the design of small molecule inhibitors 
targeting this interaction.  
 
Intensive biochemical and structural analysis led by our collaborators (J. De Rijck, K. 
Cermakova, KU LEUVEN, Belgium) further allowed the identification of two MLL-
LEDGF/p75 targetable interfaces. Indeed a recently resolved partial structure revealed a 
potentially drugable hydrophobic pocked stabilizing the MLL-MENIN-LEDGF/p75 interface. 
Interestingly, our IBD-derived LEDGF/p75424-435 fragment was targeting this interface that 
seems to be dependent on the interaction with MENIN and has been
successfully targeted by MENIN small molecule inhibitors. As the available X-ray data 
represented only a partial structure of the LEDGF/p75-MLL-MENIN complex, our 
collaborators used NMR spectroscopy to identify an additional MLL-LEDGF/p75 interface, 
which partially overlaps with the binding site of known LEDGF/p75 interactors including the 
HIV-1 integrase. They proved that binding of the HIV-1 integrase or MLL to LEDGF/p75 is 
mutually exclusive and seems to be dependent of MENIN. Importantly, the newly defined 
interface was directly targeted by expression of the LEDGF/p75375-386 IBD-derived 
fragment we previously defined. We were then able to show that the clonogenic growth of 
primary murine MLL-AF9 expressing leukemic blasts was selectively impaired upon 
overexpression of a LEDGF/p75 binding cyclic peptide CP65, known to bind the IBD and 
disrupt its interaction with HIV-1 integrase. Thus collectively our data shows that this newly 
defined protein-protein interface represents a new target for the development of 
therapeutics against HIV-1 replication as well as LEDGF/p75-dependent MLL fusion 
oncoprotein driven leukemic disorders.  
 
Intensive research efforts led by many groups resulted in the definition of multiple 
possibilities for potential interference with the leukemogenic MLL fusion protein complex. 
We therefore also started to explore whether targeting of the MLL complex at different 
nodes could result in synergistic effects to efficiently impair MLL-fusion mediated leukemia. 
Previous studies have shown that the histone H3 lysine 79 (H3K79) methyltransferase 
DOT1L is essential for MLL-fusion driven leukemogenesis. Selective small molecule 
DOT1L inhibitors have been generated and are currently entering first clinical trials. 
However, when given in monotherapy, work in mouse models has shown limited and slow 
responses to these compounds in many MLL-rearranged leukemia models. Collaborators 
from the Novartis Institute for Biomedical Research (NIBR, Basel) have performed shRNA 
screens in MLL-rearranged cell lines to identify sensitizing targets for DOT1L inhibitors and 
found that knockdown of several MLL complex components, including LEDGF/p75 
significantly enhanced anti-leukemic responses. In absence of any available 
pharmacological agents targeting LEDGF/p75, they decided to test syngertistic activity of 
the DOT1L inhibitor EPZ004777 in combination with the MENIN inhibitor MI-2-2 previously 
shown to induce growth arrest and differentiation in MLL-rearranged leukemia cells. We 
therefore tested the effects of combination of MI-2-2 and EPZ004777 in our MLL-AF9 
mouse AML model and found that transient and non-lethal exposure to the combination of 
these compounds was sufficient to permanently disable their leukemogenic infiltrating 
potential in vivo mainly through induction of a rapid and effective differentiation of MLL-
AF9 expressing leukemic blasts. Altogether, these results suggested that the 
EPZ004777/MI-2-2 combination might deliver synergistic and durable anti-leukemia effects 
in MLL-rearranged AML. 
 
All together this work suggests that the MENIN-MLL-LEDGF/p75 complex offers several 
interfaces for selective therapeutic targeting for MLL-rerranged acute leukemia. In 
addition, our results suggest that co-targeting the MLL complex at different nodes could 
pave the way for selective and efficient novel therapeutic approaches for leukemic 
disorders mediated by MLL fusion oncoproteins. Such approaches need to be clinically 
tested in particular whether they will be able to overcome early relapse of the disease that 
is the “Achilles heel” of current applied polychemotherapeutic strategies.  
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INTRODUCTION 
1. BLOOD FORMATION-HEMATOPOIESIS 
 
 The hematopoietic system is responsible for numerous critical functions for 
mammalian physiology including oxygen and nutrients transports as well as immune 
defense. With around 3 x109 new cells produced daily in the adult human bone marrow 
(BM), blood is one of the most highly regenerative tissue of the human body. The entire 
hematopoietic system is maintained by hematopoietic stem cells (HSCs), a rare cell entity 
found in the BM of adult mammals. The hematopoietic system is derived from the 
mesoderm lineage in the developing embryo in a process called developmental 
hematopoiesis divided in 2 steps: (1) embryonic hematopoiesis and (2) definitive 
hematopoiesis (Fig.1) 1,2.  
 
 
Fig. 1: Blood formation development in the mouse 
 
Schematic representation of blood formation in the mouse embryo. The process starts at E6.5 by a phase 
called embryonic hematopoiesis. Here the cells migrate from the mesoderm instructed to form blood through 
the primitive streak to the extraembryonic region. This leads to the formation of the yolk sac where 
hemangioblasts are thought to differentiate into endothelial cells and primitive erythroblast, thus forming the 
yolk sac blood islands. A second wave of definitive hematopoiesis is initiated in the fetal liver at E10.5, when 
the liver rudiment is deeded by incoming HSCs though to be generated through budding of cells lining the 
ventral floor of the dorsal aorta. Later in fetal development hematopoiesis shifts to bone marrow, the place of 
adult blood cell formation. (Figure adapted from 1). 
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Although adult HSCs remain mostly quiescent, they can enter the cell cycle and either self-
renew or differentiate into multi-potent progenitors that give rise to a while diversity of 
mature blood cells, resulting in a well described hierarchy of blood cells that maintain 
homeostasis. This organized pyramidal representation is based on the ability of HSCs to 
self-renewal symmetrically, producing two daughters HSC, or asymmetrically, resulting in 
one HSC and another downstream progenitor that possesses a reduced capacity for self-
renewal. The HSC population can also be activated and expanded in response to stress 
conditions such as infections or blood loss. In the hematopoietic system, stem and 
progenitor cells account for less than 0.01-0.05% of the cells in the bone marrow and are 
divided in three different populations according to their ability to self-renew. Long-term 
HSCs (LT-HSCs) give rise to short-term HSCs, which in turn give rise to more restricted 
progenitors (Fig. 2). During this process, the cells gradually lose their self-renewing 
capacity and become mitotically more active 3,4. 
Cellular immunophenotyping of the blood system 
In the last decade intensive efforts have been undertaken to characterize HSCs and 
committed progenitor cells, mostly by definition of specific surface markers that can be 
used for immunophenotyping to study the cells of a particular level of the hierarchy. Mature 
blood cells express specific markers at their surface, e.g., Mac-1 (CD11b) or Gr-1 
(Ly6G/6C) for macrophages and granulocytes respectively, CD3 for T lymphocytes, B220 
for B cells and Ter119 for erythroid cells. HSCs do not express substantial amounts of 
these lineage markers (Lin-/lo), and this property is therefore used to enrich bone marrow 
for HSCs and early progenitors. At the opposite, immature progenitor cells express the 
antigens CD34, C-kit and Sca-1 in the mouse, and this specificity can be exploited to 
positively select HSCs. Inside the murine HSCs compartment, long-term (LT) HSCs can 
be isolated using their specific positivity for CD150 and negativity for FLK2. In Humans, 
the LT-HSCs pool is phenotypically characterized as lineage markers negative, CD34+, 
CD38- and CD90+. Metabolic criteria, such as low uptake of rhodamine dye or Hoechst 
stain can also be used to enrich HSCs. Additionally, individual progenitor cells that are 
committed to either myeloid or lymphoid fate can also be isolated by immunophenotype. 
For example, CLPs (Common Lymphoid Progenitors) can be isolated based on expression 
of interleukin- (IL)-7 receptor and their progeny can be further distinguished for B and T 
cell fates. Identically, CMPs (Common Myeloid Progenitors) can be distinguished thanks to 
expression of CD34 and FcγR for granulocyte-monocyte (GM) fate vs. a megakaryocytic-
erythroid (Meg-E) fate. Combination of these approaches is used to isolate immature vs. 
 3 
mature bone marrow cells and permits prospective isolation of subsets of hematopoietic 
cells for analysis of growth characteristics, gene expression and regulators of cells fate, 
survival, and differentiation5. A major strength of the mouse hematopoietic system is the 
ability to transplant distinct stem cells or committed progenitors subpopulation or even 
single cells using their immunophenotype specificity. In vivo functionality is based on the 
ability of transplanted cell to re-build a complete blood system in recipients that had their 
hematopoietic system destroyed either by exposure to gamma radiation or by cytotoxic 
drugs 2. 
 
 
 
Fig. 2: HSCs differentiation tree 
 
Illustration of the hematopoietic lineage tree. HSCs differentiate through progressively more committed 
progenitors giving rise to all the mature blood cell types with diverse functions divided into myeloid and 
lymphoid cells. The hematopoietic tree shows stable cell populations, which have been defined by surface 
marker expression (indicated next to the according cell population), although the exact branching points and 
potential of progenitors are still in debate. HSC hematopoietic stem cell, LT long-term, ST short-term, MPP 
multi-potent progenitors, CLP common lymphoid progenitors, GMP granulocyte monocyte progenitor, MEP 
myeloerythroid progenitor, RBC red blood cell, Lin Lineage, lo low, hi high. (Figure adapted from 2).  
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Transcriptional regulation of the hematopoietic system 
Hematopoietic system development and functions are both tightly controlled at the level of 
gene transcription. Efforts have been made to identify key regulators of the hematopoiesis 
developmental stages and transitions and the use of ES cells to introduce knockout gene 
into embryos has been invaluable 6. For example, Scl-/- mouse embryos die at around E9.5 
with an absence of hematopoietic cells, while other mesodermal lineages are unaffected. 
This observation constituted the first evidence that Scl gene (also known as tal1) encoding 
a basic helix-loop-helix protein seems to be essential for HSCs specification. In the same 
vein, Runx1 (also known as Aml1) gene knock out in mouse is embryonically lethal at 
E12.5. Scl-/- embryos die of severe hemorrhaging and hematopoietic clusters fail to form in 
the dorsal aorta 7. The use of specific constitutive Cre-recombinase mouse line ablators 
expressed at specific embryonic stages allowed defining temporal window activity of those 
genes 6. Among others, Runx1 ablation mediated by VE-Cadherin-Cre, restricted to 
endothelial cells of the yolk sac, causes severe defects in hematopoiesis. Conversely, its 
ablation upon VAV1-Cre, restricted to hematopoietic cells and downstream of Runx1, does 
not affect viability of fetal or adult derived blood cells. This study highlighted the exclusive 
requirement of Runx1 in the endothelial-to-hematopoietic transition 8. 
Others TFs has been found to be crucial for HSCs differentiation and blood homeostasis. 
Concretely, among others, Pu-1 overexpression blocks erythroid differentiation, and its 
genetic disruption in mice causes embryonic lethality between days E16.5 and E18.5 
mainly associated with a block in myelopoiesis and B lymphopoieisis 5. These results 
strongly suggest that Pu-1 (Spi1) stimulates myeloid development and block 
erythropoiesis. At the contrary, targeted mutagenesis in the Gata-1 gene in mouse blocked 
primitive and definitive erythropoiesis highlighting the key role of Gata-1 in erythro-
megakaryocytic speciation and differentiation 9,10.   
In summary, blood cell formation involves a progressive restriction to differentiation 
potential and the establishment of lineage-specific expression profiles relying on lineage-
specific transcription factors (TFs) (Fig. 3).  
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Fig. 3: Transcriptional regulation of HSCs development and differentiation 
 
During mouse embryonic development, hematopoietic cells develop from the embryonic mesoderm through 
a hemangioblast intermediate. The transcription factor SCL then regulates the transition from hemangioblast 
to hemogenic endothelium state. The production of HSCs through budding of hemogenic endothelium is 
related by RUNX1 expression. From the end of embryonic stage to the adulthood, several lineage-specific 
transcription factors are involved in HSCs differentiation, e.g. GATA-1 is the master regulator of MEP 
development and erythro-megakaryocytic differentiation or PU-1 which is playing an essential role during 
myeloid development and differentiation (Figure adapted from 6). 
 
Epigenetic regulation in hematopoiesis 
Another key dynamic process important for hematopoiesis is the recruitment of epigenetic 
modifying enzymes in order to open up chromatin and allow binding of essential TFs to the 
promoter/enhancers of their target genes. Remodeling of chromatin is taking place as cells 
differentiate, until an irreversible state is reached that is specific to terminally differentiated 
cell. The organization of DNA into higher order structure or nucleosomes is a central 
component of epigenetic gene regulation. Each nucleosome, representing the basic 
repeating unit of chromatin, consists of DNA that is tightly wrapped around a core of eight 
histone proteins including two molecules of each H2A, H2B, H3 and H4. Individual 
nucleosomes are linked to each other by the linker histone H1 and a short length of DNA 
11. Epigenetics is commonly used to describe the chromatin-based events including DNA 
methylation, histone modifications and chromatin structure that affect gene expression. If 
we focus on histones protein, their tail regions are subject to a large variety of post-
translational modifications such as acetylation, methylation, phosphorylation, 
ubiquitination, or adenosine diphosphate-ribosylation. These epigenetics modifications at 
DNA and histones levels can change chromatin structure and serve as platform for the 
binding of reading proteins that recruit additional chromatin-modifying proteins and 
enzymes. These multi-protein complexes then modulate transcriptional activation and 
repression, DNA replication, recombination and repair. A key role for hematopoiesis 
resides in the interplay between Polycomb-group (PcG) and Trithorax-group (TrxG) 
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complex through their histone lysine (K) methyltransferases (HKMTs) activity (Fig. 4). Both 
of these complexes have been firstly described in Drosophila melanogaster as important 
regulators of tissue homeostasis and body plan formation 12. Indeed mutation in PcG or 
TrxG proteins in the fruit fly leads to loss of cellular memory and homeotic transformation 
involving either duplication or loss of body structures, mainly linked to deregulated 
expression of highly conserved bithritorax complex (BX-C) homeotic genes (human 
homolog: Homeobox=Hox genes) 13,14. Concerning their functionality, the Polycomb 
repressive complex 2 (PRC2) is setting on chromatin the repressive histone mark H3K27 
tri-methylation (me3) through EZH2 methyltransferase activity, and the TrxG complex 
includes Thritorax methylase (TRX) as a core component, which mediates the H3K4me3 
activation mark. In hematopoiesis, the counteraction of PcG and TrxG complexes leads to 
proper expression of Hox genes in a context-dependent manner 15–17.  
 
 
 
Fig. 4: Key players in epigenetic regulation of hematopoiesis 
 
Schematic representation of a key epigenetic regulatory mechanism of hematopoiesis. DNA 
methylation and repressive histone marks such as H3K27me3 mediated by the EZH1/2 
methyltransferases from the PRC2 are counterbalanced by histone hyperacetylation and activating 
histone marks like H3K4me3 exerted by TrxG proteins such as the MLL methyltransferase (human 
homolog of TRX). Repressive marks set by the PCR2 complex keeps chromatin in a 
transcriptionally inactive or “closed” state whereas TrxG complex function as an “anti-silencer” 
keeps chromatin in an “opened” conformation to activate the expression. The balance between 
PcG and TrxG of proteins allows appropriate expression of homeotic genes essential for proper 
blood formation. PcG polycomb group, PRC polycomb repressive complex, me3 tri-methylation, 
TrxG trythorax group, MLL Mixed Lineage Leukemia protein (Figure adapted from 15,17). 
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Several of the epigenetic and transcriptional factors mentioned above were identified by 
virtue of their involvement in chromosomal abnormalities associated with various types of 
hematological disorders in particular acute leukemia. 
 
2. LEUKEMIA, A CANCER OF THE HEMATOPOIETIC SYSTEM 
  
 Leukemia is defined as a cancer of the blood formation and characterized by 
abnormal accumulation of white blood cells in hematopoietic organs. This malignancy is 
grouped in different clinical and pathological entities. Acute leukemia is characterized by 
an increase of immature bloods cells with aberrant differentiation that do not perform 
normal function, whereas chronic leukemia is defined by an abnormal accumulation of 
mostly terminally differentiated blood cells. According to the affected cell lineage, leukemia 
is subdivides into myeloid leukemia involving granulocytic, monocytic, erythroid or 
megakaryocytic cell lineage, vs. lymphocytic leukemia including B-cell, T cell or natural 
killer (NK)-cell lineages. Based on this classification, four main leukemia categories are 
defined namely acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute 
lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). ALL occurs more 
frequently in children, whereas CLL affects more adults over the age of 55. AML and CML 
are also more frequent in the elderly affecting mostly individuals over 60y (Table I) 18. 
The standard treatment regimen for most forms of leukemia consists in multi-drug 
chemotherapy with combinations that are different for the leukemia subtypes. In 
combination with allogeneic or autologous bone marrow transplantation chemotherapy can 
lead to cure for some patients. However a large fraction of patients with acute leukemia 
relapse and ultimately die from their disease. Particularly, elderly patients unable to 
support aggressive chemotherapy regimens have limited therapeutic options. In the past 
decade, intensive research efforts aimed to identify compounds targeting specifically 
leukemic cells. Indeed the first successful anti-leukemic small molecules are protein 
tyrosine kinase inhibitors (TKI) like Imatinib (Gleevec®) that have revolutionized the 
therapy of chronic myeloid leukemia (CML) with a five-year overall survival of 90% 19. The 
potency of such molecules is based on the fact that in almost all patients with CML the 
cells are driven by the constitutively active BCR-ABL fusion tyrosine kinase resulting from 
a t(9;22)(q34;q11.2) chromosomal translocation. However when CML turned into blast 
crisis upon acquisition of secondary mutation, kinase inhibitors are not as potent than in 
the chronic phase of the disease. Another good example of efficient targeted leukemia 
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therapy is acute promyelocytic leukemia (APL): here the leukemic cells are driven by the 
PML-RARα fusion protein resulting from the t(15:17)(q24;q21) chromosomal translocation. 
Very recent work has shown that the combination of all-trans retinoid acid (ATRA) and 
arsenic trioxide is able to inactivate the PML-RARα fusion and to cure >90% of the 
patients 20. Beyond APL, there is currently no clinically efficient targeted therapy for other 
froms of acute leukemias. Nevertheless polychemotherapy achieves initial remission in 
about 70% of the AML patients, but the five-year survival is below 40% as most of the 
patients relapse within 5 years despite continued treatment 21. In particular, patients over 
the age of 60 face an overall poor prognosis of 10-20% survivors for more than 5 years 22. 
Facing this bottleneck, acute leukemia treatment aims to shift from a uniform approach to 
more personalized therapies targeting the underlying molecular alterations identified as 
initiator and driver of the disease. 
 
Table I: Leukemia subtypes classification 
Subtype Age (year) Cellular Origin Comments 
ALL <15 HSC? 
B-cell > T-cell 
Poorer prognosis for adults than children, 
>80% of B-ALL in children can be cured 
AML all, most 
>60 
HSC 
Myeloblast? 
Promyelocyte? 
 
Poor prognosis, relapse 
Heterogeneous tumor populations 
Best prognosis with bone marrow 
transplantation 
CML >50 HSC Prognosis improved by TKI 
t(9;22) “Philadelphia chromosome” in 
>90% of cases 
Acceleration into “blast crisis”  
CLL >50 HSC? 
B-cell 
Currently not cured 
Long course with rare conversion to acute 
form 
 
First evidence from stem cell biology has provided insights into cancer biology by 
underlining the relationship between stem cell and tumor cells. This axe of thinking 
suggests that tumors might contain some cancer stem cells that are able to initiate the 
disease in a hierarchical manner. Interestingly in the context of leukemia, biological studies 
on human AML have shown that only 0.1 to 1% of leukemic cells have the capacity to 
initiate the disease in severe combined immunodeficient (SCID) mice 23,24. These findings 
strongly suggest that similar to normal hematopoiesis, leukemia might be composed by 
cells with different phenotypic characteristic as well as proliferative and self-renewal 
potentials. Only a small number of cancer cells are able to restore themselves and 
maintain leukemia, whereas the majority of leukemic cells are in more “mature” state and 
unable to initiate the disease. This cellular entity responsible of initiating and maintaining 
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leukemia has been described as “leukemic stem cells” (LSCs) or leukemia-initiating cells 
(LICs) and share some self-renewal and differentiation capacities with normal HSCs 25. 
Given this common attributes, it has been proposed that acute leukemia might be initiated 
by transforming events arising in HSCs. Alternatively leukemias might initiate from more 
committed progenitors that have acquired transforming mutations that overcome their 
limited self-renewal potential. Experimental evidence suggests that AML and CML arise 
from mutations in HSCs. Indeed for most AML categories, except for APL, the unique cells 
able to transplant AML in NOD/SCID (Nonobese diabetic/severe combined 
immunodeficient) mice have a [CD34+, CD38-] phenotype characteristic of the HSCs pool 
whereas the [CD34+,CD38+] leukemic cell fraction cannot transfer the disease to mice 24. 
Nevertheless even if HSCs are often the target of genetic events leading to malignant 
transformation, committed progenitors or even mature cells may also be transformed. 
Actually in the case of APL, it has been shown that the APL-related aberrant fusion gene 
PML/retinoic acid receptor α (RARα) was present in [CD34-,CD38+] cell populations but 
not in the [CD34+,CD38-] HSC-enriched cell fraction 26. This observation suggests that APL 
leukemogenesis might originate from a more differentiated cell type than HSC like 
pluripotent progenitors. In CML, the aberrant Philadelphia chromosome leading to the 
constitutively active p210BCR-ABL fusion protein kinase occurs in HSCs and GMPs might 
acquire additional mutations leading to acceleration and blast crisis 27,28. To corroborate 
this idea, thanks to the use of promoter elements of myeloid-specific gene such as human 
MRP8 (hMRP8) promoter, transgenic mice expressing human leukemic oncogene 
specifically in committed myeloid cells have been generated. Indeed MRP8 encodes a 
small calcium-binding protein expressed in neutrophils, monocytes, and their immediate 
progenitors, CMPs and GMPs, but not in HSCs 29. Interestingly, transgenic mice 
expressing BCR-ABL from this promoter developed CML like disease 30, and mice 
expressing PML-RARα from hMRP8 developed a preleukemic state which eventually 
evolves in APL similar to human patient harboring the same translocation 31. 
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3. ACUTE MYELOID LEUEKEMIA AS A PRODUCT OF FUNCTIONALLY 
COLLABORATING GENETIC AND EPIGENETIC ALTERATONS 
 
 Normal development underlies a delicate balance between self-renewal and cellular 
differentiation. When these two processes become deregulated or are uncoupled, acute 
leukemia can develop.  
Developed in the 60’s conventional cytogenetic analysis started to uncover the presence 
of chromosomal translocations, large deletions and inversions in leukemic cells. Indeed, 
main clues to the genetic basis of acute leukemia initially came from cloning of recurring 
breakpoints of mostly balanced chromosomal translocations associated with specific 
disease phenotypes. Successively, improved sequence analysis tools revealed the 
existence of smaller mutations such as point mutations, microdeletions particular in cases 
in which conventional cytogenetic analysis did not found any alterations. Collectively, two 
decades of clinical and experimental research revealed that acute leukemia is the product 
of a multistep process involving multiple collaborative genetic molecular aberrations. The 
leukemogenic potential of a large number of these genetic alterations has been 
characterized in vitro and in vivo. Based on their cellular activity, it has been proposed to 
classify leukemia-associated genetic lesions into two major categories. The “class I 
mutations” generally include gain of function mutations that lead to aberrant activation of 
signaling transduction pathways conferring cell survival and proliferation advantages. The 
“class II mutations” consist mostly of lesions that directly alter transcriptional programs 
essential for normal hematopoietic differentiation resulting in aberrant self-renewal and 
maturation arrest 32,33. Here we will focus mainly on acute myeloid leukemia (AML), which 
is one of the best-characterized and studied developmental models for acute leukemia. 
Class I mutations: protein kinases - signaling mediators 
The best-studied examples of AML-associated class I mutations are alterations in genes 
encoding for protein tyrosine kinases (PTKs e.g. FLT3 and KIT) and the RAS protein 
family members. Leukemia-associated PTK mutations generally lead to constitutive 
activation and uncontrolled stimulation of downstream effectors such as the signal 
transducers and activators of transcription (STAT) family members resulting in increased 
proliferation and survival of the cells. In AML the most prevalent class I mutations affect 
the FLT3 receptor tyrosine kinase, including internal tandem duplications (ITDs) or 
activating point mutations in the kinase domain. FLT3-ITDs are the most frequent AML-
associated PTK mutations found in up to 30% of adult patients and associated with 
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increased risk of relapse and/or short survival 34. Commonly the ITDs are located in the 
juxtamembrane domain, but, in 28% of cases, the duplication is integrated in the tyrosine 
kinase domain (TKD), and associated with particularly poor outcome of the disease 35. In 
addition to ITDs, point mutations mainly localized in the TKD are found in 7-10 % of 
cytogenetically normal AML patients 36. Both types of FLT3 mutations lead to constitutive 
and enhanced activation of several downstream signals such as RAS, MAPK or STAT5. 
Constitutive activation of the RAS pathway can also arise from mutations in RAS itself. 
NRAS, KRAS and HRAS are a family of guanine nucleotide binding proteins, which are 
frequently found downstream of tyrosine kinase receptors and involved in development 
and tissue homeostasis 37. NRAS and KRAS point mutations (typically in codons 12, 13, 
and 61) are found in up to 40% of AML patients. These alterations lead to inactivation of 
the intrinsic GTPase activity, which in turn results in constitutive activation of RAS proteins 
37. Intriguingly, multiple studies have shown that expression of “class I mutations” in murine 
bone marrow mostly gives rise to myeloproliferative disease (MPD) but is not sufficient to 
induce an AML phenotype 33. MPD is characterized by expansion of mostly normally 
differentiating cells, suggesting that class I mutations do not lead to a differentiation block 
and aberrant self-renewal capacity characterizing AML. 
Class II mutations: transcriptional regulators of hematopoietic differentiation 
AML-associated “class II mutations” include mainly genetic lesions affecting transcription 
factors (TFs) or epigenetics regulators that are important for normal hematopoiesis. These 
mutations mostly lead to impaired differentiation and increased self-renewal properties of 
hematopoietic stem and early progenitor cells (HSPCs). Many class II mutations result 
from balanced chromosomal translocations that lead to chimeric fusion proteins with 
aberrant transcriptional activity involving key regulators essential for the differentiation 
program of HSPCs such as the core-binding factor (CBF) or the retinoid acid receptor 
alpha (RARα). CBF is a heterodimeric complex composed by the two subunits, AML1 
(RUNX1) and CBFβ both essential for normal hematopoiesis development 38. About 10-20 
% of adult AML cases carry translocations involving CBF components such as 
t(8;21)(q22;q22) or inv(16)(p13;q22) resulting in AML1-ETO and CBFβ-MYH11 fusion 
genes respectively 39. As mentioned before, translocations involving RARα on 
chromosome 15 are a hallmark of APL. The most common translocation in APL, which 
account for 4% of disease cases, is t(15;17)(q24;q21) leading to the PML-RARα fusion 40 . 
Functional studies suggested that fusions like AML1-ETO or PML-RARα act mainly in a 
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dominant negative fashion to the wild-type protein by aberrant recruitment of histone 
deacetylase co-repressors 41,42.  
Another recurrently altered hematopoietic transcriptional regulators in AML is the mixed 
lineage leukemia (MLL1 also known as ALL-1) gene on the long arm of chromosome 11 43. 
MLL1 is part of over 120 different translocations leading to fusions oncogenes. Normally 
MLL1 is part of a large multi-protein complex that is able to regulate activation of the Hox 
genes cluster 44,45. Hox cluster genes A, B and C are highly expressed in hematopoietic 
stem and progenitor cells and responsible for maintenance of the stem cell and 
progenitors pools 46–48. Similarly, Hox cluster genes are themselves involved in a series of 
translocations implicating the nucleopore protein 98 (NUP98). Several of them including 
NUP98-HOXA9, NUP98-HOXD13 or NUP98-HHEX have been shown to have a 
leukemogenic potential in the mouse 49–51. These observations strongly suggest a key role 
of aberrant Hox genes expression in leukemic hematopoiesis. In addition to chimeric 
transcription factor fusions, some, mostly “loss of function” point mutations are found in 
hematopoietic TFs including CEBP/α and PU-1 5,33. Several studies have shown that in 
contrast to class I mutations, retroviral or transgenic expression of class II mutations in the 
bone marrow of the mouse led to development of dysplastic hematopoiesis or AML-like 
phenotypes 36. However, in most cases a relatively long latency was required for the 
induction of the disease, which suggests that the class II mutations might be crucial but by 
themselves not sufficient for the onset of AML. 
Functional cooperation between class-I and -II mutations in acute leukemia 
Several studies reported that a given AML patient often carries mutations of both classes 
but rarely more than one mutation of each complementation group. Indeed, 30% of the 
patients with APL have in addition of the hallmark PML-RARα fusion a FLT3 activating 
mutation. In some cases, the evolution from a chronic MPD harboring a class I mutation 
like the BCR-ABL, TEL-PDGFRβ fusions or the JAK2V617F mutation to AML correlated with 
the acquisition of a class II mutation such as AML1-EVI1, AML1-ETO or NUP98-HOXA9 
fusion genes 52. Even though these observations strongly proposed a “cooperation model” 
between class I and class II mutations for leukemogenesis they were still many patients in 
which no such mutations could be found.   
Nevertheless functional cooperation between class I and class II mutations could be 
demonstrated in several AML mouse models. Cooperation between PML-RARa and FLT3-
ITD was demonstrated in a transgenic mouse model. In fact, solely transgenic expression 
of PML-RARα leads to APL-like disease after long latency and incomplete penetrance, but 
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retroviral expression of FLT3-ITD in bone marrow of these mice induced APL after a 
shorter latency and complete penetrance 53. Several additional publications corroborated 
the involvement of FLT3 mutations as a functional cooperator for AML. Retroviral co-
expression experiments in murine bone marrow cells have demonstrated a potentiation 
effect on AML induction when FLT3-ITD was expressed in combination with several class 
II mutations including CBFβ-MYH11 (inv16), MLL-AF9, or NUP98-NSD1 54–56. 
Modern genomics and the clonal evolution concept in AML 
The development of more powerful sequencing tools able to read the entire AML genome 
revealed that genetic alterations in AML seem to be somehow more complex than 
suggested in the simple “class I – class II complementation model”. As whole genome 
sequence data of more and more AML patients become available a novel concept of 
stepwise acquisition of genetic alterations giving rise to clonal heterogeneity with subclonal 
architecture in AML arose 57.  
The AML Cancer Genome atlas project, which characterized the somatic genomes of 50 
patients with de novo AML and the somatic exomes of 150 others cases, represents a 
milestone in our understanding of hematological malignancies 58. Hereby 2585 somatic 
mutations, insertions, and deletions in coding regions of AML genomes were found with a 
frequency of more than 5% in de novo AML. Strikingly, despite this high number of genetic 
lesions, a low average number of 13 mutations was found in a given individual. These 
findings enforced the concept of “driver mutations” causing leukemic transformation. 
However, these leading mutations occur in the same time with so-called “passenger 
mutations” lacking transforming capacity, but accumulating during clonal progression and 
carried along with the leukemic clone. 23 genes have been reported as substantially 
mutated in AML and have been categorized in 9 different functional classes (Fig. 5). There 
is also mutations in genes that could not be assigned to class I or class II alterations 59. As 
example, mutations in the nuclear protein nuclephosmin (NPM1) are present in about 30% 
of AML patients with no leading cytogenetically detectable chromosomal alterations 57,59. In 
AML the proportion of cases with normal karyotypes is quite frequent (≈50%). To better 
understand clonal evolution of those cytogenetically normal AML, Welch et al., proposed to 
compare sequenced genomes of patients with known initiating mutation (PML-RARα) with 
sequenced genomes that have less known initiating events vs. exomes of healthy donor 
HSPCs 60.  This study overall suggest that most of the mutations found in AML genomes 
are actually random events occurring in HSPCs giving rise to a clonal signature before 
they acquired the initiating mutation. In many cases, only one or two additional cooperating 
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mutations were sufficient to generate the malignant clone 60. Additionally, deep sequencing 
allows tracking and quantifying AML subclones based on the presence of different 
mutations. Interestingly, some mutations present in an AML sample at diagnosis are stably 
maintained and found back in the same AML sample upon relapse. However, most AML 
patients acquire additional genetic modifications during the course of the disease which 
are rarely lost subsequently suggesting that AML relapse originates from incomplete 
eradication of founder clones, rather than from development of new malignant clones 61,62. 
However, two very recent studies report that preleukemic mutations in HSPCs provide a 
chemotherapy resistance phenotype 63,64. These genetic alterations occur independently of 
the first diagnosed AML driver genetic event and target mainly epigenetic modifiers (e.g. 
DMNT3, IDH2). Subsequently, occurrence of these preleukemic mutations seems to allow 
expansion of a chemoresistant preleukemic clone that is susceptible to acquire a new 
initiating mutation leading in turn to disease relapse.  
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Fig. 5: The Clonal selection model in acute leukemia 
 
In general in acute leukemia, genetic alterations can nowadays be categorized in two types: the “driver 
mutations” possessing the transforming activity, and the “passenger mutations” lacking leukemogenic 
potential but accumulating during disease progression and participating in the set up of a leukemic clonal 
signature associated with favorable or poor disease prognosis and chemotherapy resistance. Cooperation 
between these two categories of genetics alterations leads to the selection of a clone able to rapidly induce 
acute leukemia in mice.  All recurrent human mutations have been classified in 9 categories. AML genetic 
alterations can target proteins kinases or other signaling proteins and provide proliferative and/or survival 
advantages through activation of TFs such as STAT. Several classes include recurrent mutation in 
epigenetic modifiers such as EZH2 and MLL1, or proteins involved in chromatin remodeling such as cohesin 
complex proteins, enabling aberrant expression of key oncogenic genes signature like the Hox-A cluster 
genes. Some single mutation in driver genes involved in key regulatory mechanisms for hematopoiesis such 
as translocation involving e.g. MLL or AML1 are sufficient to induce a block in differentiation providing 
aberrant self-renewal capacity to the target cell and lead to the onset of a MDS or acute leukemia-like 
disease after a long latency in mouse models. 
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4. THE MIXED LINEAGE LEUKEMIA GENE & ACUTE LEUKEMIA 
 
The Mll1 (Mixed Lineage Leukemia, here referred as MLL) gene is one of the most 
frequently affected genes by class II mutations associated with aggressive human acute 
leukemias. In the leukemia context, MLL gene, also known as All1, Htrx or Hrx, is involved 
mainly in balanced chromosomal translocations resulting in novel chimeric fusion proteins 
containing the amino terminal part of MLL fused in-frame with the carboxy-terminal portion 
of over 50 different partner proteins 65. MLL rearrangements affecting either the lymphoid 
or myeloid lineage constitute up to 80% of infant leukemia (<1 year of life), 10 % of 
childhood leukemia (2-18y), and approximately 5-10% of adult acute leukemias 66. Apart 
from spontaneously arising leukemia, MLL fusion proteins are frequently found in patients 
with therapy-related leukemias particularly occurring after treatment with topoisomerase II 
inhibitors, which represent 5 to 10% of the MLL-associated leukemias 67. In general, MLL 
genetic alterations are often hallmarks of early relapse and poor survival 65–67. 
Functional and structural overview of the wild-type (WT) MLL gene 
The MLL gene is located on the long arm of the chromosome 11 (11q23) and contains 37 
exons spanning over 92kb of genomic DNA. The largest open reading frame leads to a 
transcript of around 12kb encoding for a large multi-domain protein of 430KDa recognized 
as the mammalian homolog of the trithorax gene in Drosophila. The evolutionarily 
conserved trithorax group (trxG) family of proteins is known to positively regulate 
transcription of Antennapedia (ANT) and Bithorax (BX) homeotic genes complexes 68. 
Indeed in the fruit fly mutations in Thritorax mimic the phenotypes of loss-of-function- 
mutations in multiple ANT and BX complexes genes leading to homeotic transformation of 
the thoracic and abdominal segmentation 13,69. MLL regulates target gene expression 
based on its abilities to bind to DNA and to methylate the lysine 4 residue of histone H3 
(H3K4) through its C-terminal SET (Suppressor of variegation, Enhancer of zeste, 
Trithorax) domain. MLL is crucial for maintaining the activation of a large number of genes 
including the Hox clusters genes during embryogenesis, hematopoiesis, and 
neurogenesis. Indeed, homozygous deletion of the MLL gene in the mouse resulted in an 
embryonically lethal phenotype due to disturbed HOX-mediated body plan formation, 
highlighting MLL maintained Hox gene expression as an essential mechanism for 
embryogenesis 70. Interestingly, in this null mouse, the MLL-deficient HSPCs from the yolk 
sac and fetal liver were impaired in self-renewal and proliferation mostly linked to decrease 
expression of Hox-A cluster genes 71–73. Notably, using an in vitro ES-cell differentiation 
model it was shown that the block in hematopoiesis could be rescued by reintroducing 
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individually Hoxa9, Hoxa10 and Hoxb4 72. In contrast, a recent study report that 
developmentally VAVCre induced constitutive MLL loss in mice is deleterious only for 
postnatal hematopoiesis and results in global ineffective blood system formation leading to 
lethality 3 weeks after birth 74. Furthermore, conditional ablation of MLL in the adult murine 
hematopoietic system leads to fatal bone marrow failure within three weeks. This break in 
hematopoiesis was reflected by impaired proliferation and response to cytokine-induced 
cell-cycle entry of hematopoietic progenitors and depletion of quiescent HSCs 75,76. Taken 
together these observations strongly support that the key role of MLL appears to be 
maintenance of the HSPCs compartments mainly through regulation of Hox genes. 
However it remains elusive if the MLL function is essential for both developmental and 
definitive hematopoiesis or only for post-natal hematopoiesis.  
 
The MLL protein is constitutes of two subunits arising from proteolytic cleavage by 
taspase1. Taspase1 null mice showed homeotic transformation due to improper Hox 
genes expression underlined the importance of cleavage for developmental functions of 
MLL 77. The N-terminal MLL (MLL-N; 300/320KDa) contains several domains with 
transcriptional co-activator activity [e.g. plant homeodomain fingers = PHD, DNA binding 
motifs such as AT-hooks, CXXC-zinc finger], which set a platform for recruitment of 
proteins regulation of specific gene expression. The C-terminal MLL (MLL-C; 180KDa) 
comprises the SET methyltransferase domain 78. Some evidence highlight the SET domain 
has a key role player in transcriptional activation of Hox genes. Actually the MLLΔSet mice 
are viable, but harbor defects in skeletal development and in several Hox genes 
expression 79. In addition, MLL SET domain methyltransferase activity had been 
associated to Hox gene activation through direct binding of MLL on promoter sequences 
45. A more detailed structure of the wild-type MLL is depicted in Fig. 4a.  
MLL fusion proteins in leukemia 
Leukemia-associated chromosomal translocations are the product of a failure of proper 
DNA double strand break repair in developing HSPCs. In the MLL gene there is a 8.3kb 
breakpoint cluster region (BCR, Fig. 4a) between exons 8 and 13 that is the target of most 
MLL rearrangements. These rearrangements lead to an in-frame chimeric protein 
containing the first 8-13 exons of MLL and a variable number of exons from a fusion 
partner gene (Fig. 4b).  
 18 
 
Fig. 6: Schematic overview of wild-type MLL protein and MLL fusions 
 
(a) MLL is a nuclear protein encompassing 3969 amino acids comprising multiple functional domains. The 
mature MLL protein consists of two subunits MLL-N and MLL-C produced by cleavage of the nascent MLL 
by taspase1 and non-covalently associated through respectively FYRN and FRYC motifs. The MLL-N 
subunit contains AT-hooks motifs binding to the minor groove of AT-rich genomic DNA. Afterwards there is a 
transcriptional repression domain containing a DNA methyltransferase homology domain including histone 
deacetylase (HDAC) recruiting element and a CXXC zinc-finger motif binding to non-methylated DNA 
followed by plant homology domain (PHD) zinc-finger motifs. The MLL-C subunit contains a transcriptional 
activation (TA) domain that recruits co-activators such as CBP or EP300 and precedes the SET domain 
(homologous to fly trithorax) possessing the H3K4 methyltransferase activity. The breakpoint cluster region 
(BCR) covers exon 8 to 13. (b) Main of the MLL fusions proteins (MLL-FPs) contains the N terminus part of 
MLL encoding the first exons until the BCR and the C-terminus of an X protein that can correspond to over 
50 fusion partner genes. An exception is the MLL-partial tandem duplication (MLL-PTD) resulting in a longer 
MLL protein consisting in the duplication and insertion of a varied number of 5 to 12 exons before exon 11 or 
12. (Figure adapted from 65,80). 
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According to the different cellular location and putative function of the fusion partner, MLL 
rearrangements have been classified in several categories 65. The first group 
encompassed translocations involving fusion of the N-terminal part of MLL gene with the 
nuclear DNA-binding proteins AF4, AF9, AF10, ENL and ELL, which all together represent 
more than 80% of MLL rearranged leukemia. Here the translocation t(9;11)(p22;q23) , 
t(11;19)(q23;p13.3) and t(4;11)(q21;q23) resulting in MLL-AF9, MLL-ENL and MLL-AF4 
fusions are the most prevalent. MLL-AF9 is frequently associated with myelo-monocytic 
AML, whereas MLL-ENL can be found in both ALL and less frequently also in AML. On the 
other side, MLL-AF4 is almost exclusively linked to B-cell ALL. The second category 
implicates cytoplasmic proteins e.g. GAS7, EEN, AF1P, AF6 and AFX, representing more 
than 10% of leukemia-associated MLL fusions. An important feature of these oncogenic 
fusions is the presence of coiled-coil dimerization domains essential for their 
transformation potential 81. A third small group of MLL fusion partners is represented by 
septins (SEPT2, SEPT5, SEPT6, SEPT9 and SEPT11), which are cytoplasmic proteins 
involved in several processes such as cell-cycle control, vesicle trafficking and 
compartmentalization of the plasma membrane 82. The histone acetyltransferases EP300 
and CBP form the fourth group of proteins fused to MLL and seem to keep their enzymatic 
activity even when they are part of the fusion 83,84. The fusion with acetyltransferases 
would participate to keep chromatin on an acetylated active state necessary for 
transcriptional activation of MLL-target genes. The last and fifth type of Mll rearrangement 
consists of an internal tandem duplication of specific exons leading to the MLL-PTD 
(partial tandem duplication) fusion, found in 5-10% of cytogenetically normal AML 85. 
MLL-fusions seem to exert their oncogenic activity through activation of a particular gene 
expression program. Because all domains within MLL-N, described as implicated in DNA 
binding are retained in the fusion protein, it seems likely that MLL fusions will share many 
target loci with wild-type MLL. As critical effectors of WT MLL regulation in embryonic 
development and hematopoiesis, Hox genes seems also to be important regulators of 
MLL-fusion leukemogenic activity. Indeed upregulation of Hox genes expression is a 
common feature of human MLL rearranged leukemias 86. Additionally, in murine bone 
marrow transformation assays and animal models, co-expression of Meis1, a 
homeodomain containing co-factor, and Hoxa9 together cause aggressive leukemia and 
can at least in part particularly compensate the requirement for an active MLL-ENL fusion 
protein 87. Interestingly, Hoxa9 expression alone is sufficient to cause leukemia in mice but 
with a much longer latency than Hoxa9/Meis1 co-expression 87. Similarly, mice 
transplanted with Hoxa9 deficient bone marrow cells retrovirally-expressing MLL-ENL 
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failed to develop leukemia 88. However, in some circumstances Hoxa9 might not be a key 
target for the oncogenicity of MLL-fusion genes.  For example Hoxa9-/- mice are still 
vulnerable to MLL-AF9 mediated leukemogemesis and MLL-GAS7 is able to transform 
Hoxa9-/- bone marrow cells 89,90. These observations suggest the importance of additional 
genes or pathways in MLL-fusion mediated leukemogenesis. Interestingly, MLL-
rearranged leukemia also harbors an embryonic stem cell (ESC) genes signature opposed 
to the adult HSCs gene profiling 91. A hallmark of this ESC signature is the activation of 
WNT/ßcatenin pathway that seems to be implicated mainly in the establishment of limitless 
self-renewing capacity but also in drug-resistance phenotype in MLL-rearranged LICs 92,93. 
Despite the new discovery of several MLL-fusion specific genes, the Hox-A deregulation 
remains until now the most important factor for MLL-fusion induced leukemogenesis and 
the best readout used in MLL rearranged leukemia. 
5. THE MLL COMPLEX IN NORMAL HEMATOPOIESIS AND LEUKEMIA 
 
 MLL is part of a large multi-protein complex. The first hints supporting this concept 
is that SET1 H3K4 methyltransferase, known as the MLL homolog in yeast, acts in a 
macromolecular complex of around 1MDa named “COMPASS” containing six other 
proteins designated according to their molecular weight on SDS-page: Cps25, 30, 35, 40, 
50 and 60. Similarly, in mammalian cells, MLL functions as part of the “COMPASS-like 
complex” 94. The main activity of COMPASS and COMPASS-like complexes seems to be 
mono-, di or trimethylation of histone3 lysine 4 (H3K4) through the conserved SET domain 
of the histone methyltransferase core component. 
Description of the MLL macromolecular complex 
After proteolysis, the MLL-C and MLL-N subunits maintain different protein-protein 
interactions leading to the formation of two large multi-protein complexes 95 (Fig. 7). The 
MLL-C portion associates with WRD5 (WD repeat-containing protein 5, Cps25 homolog), 
ASH2 (absent, small, or homeotic)-like (ASH2L; Cps60 homolog), RBBP5 (Retinoblastoma 
binding protein 5; Cps50 homolog) and MOF (MYST family acetyltransferase 1, KAT8) to 
form a COMPASS-like core complex essential for maximal enzymatic activity. In addition 
the MLL-C subunits can recruit transcriptional co-activators such as acetyltransferases 
CBP and EP300 through its TA motifs. The main role of this C-terminal complex is to 
prepare chromatin for efficient transcription. On the other side the N-terminal subunit 
guides the MLL complex to its target genes by interacting directly with DNA through its AT-
hooks and CXXC motifs, but also by binding to MENIN (MEN1) and the lens epithelium-
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derived growth factor (LEDGF/p75 also known as PSIP1) that makes contacts to 
chromatin via its PWWP domain. The CXXC domain of MLL can recruit on one hand the 
polymerase-associated factor complex (PAFc) and on the other hand repressive factors 
such as histone deacetylases (HDACs) and polycomb Group (PcG). These co-repressors 
recruitment appeared to be positively regulated by conformational changes initiated by the 
propyl-isomerase cyclophilin 33 (CYP33) enrolled through interaction with the PHD fingers 
motifs of the MLL protein 96,97. Recently it also has been reported that the CXXC domain of 
MLL binds with high affinity to nonmethylated CpG-containing-DNA to protect Hoxa9 
promoter from silencing methylation and allows its expression 98. Overall, the large MLL 
multi-protein complex orchestrates three major features of chromatin modifications: 
methylation, acetylation and nucleosome remodeling leading to proper transcriptional 
regulation of specific target genes. 
 
Fig. 7: The wild-type MLL multiprotein complex 
 
MLL is present in the cell as part of a large protein complex. MLL-N complex is mainly involved in 
DNA binding to specific genes promoter mainly through interaction with MENIN-LEDGF/p75 
complex. In addition, binding of MLL-N to non-methylated CpG-containing DNA through its CXXC 
domain participates to protect target genes promoters from methylation and silencing. MLL-N also 
interacts with transcriptional co-activators such as PAF1 complex (PAFc), but also transcriptional 
co-repressor such as the PCR1 or HDAC proteins. Recruitment of co-repressors is possible thanks 
to conformational changes exerted by the propyl-isomerase CYP33. MLL-N also tethers the MLL-C 
COMPASS like complex to the targeted genes promoter. MLL-C complex is mainly involved in the 
setting of positive DNA histone marks on the target genes promoter leading to transcription 
activation and elongation such as H3K4me3 and H4K16 acetylation elicited respectively by the 
MLL SET methyltransferase domain and MOF acetyltransferase.         
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MLL-fusion protein complexes function as super elongators of transcription 
The large number of different fusion partners to MLL raises the question how the different 
fusions lead to the same disease. There is increasing experimental evidence that provided 
potential explanations. 
First, in all common MLL-fusions the respective partners are invariably fused to MLL-N 
right after the CXXC domain. MLL fusions loose the PHD fingers and the SET domain, but 
retain the AT-hooks, CXXC domain and the interaction with MENIN and LEDGF/p75 
essential for association with chromatin. Importantly, the interaction with MENIN-
LEDGF/p75 complex has been shown to be essential for MLL-fusion-induced leukemia 
99,100. The MLL-fusions also keep the ability to interact with PAFc through its CXXC 
domain. Notably, PAFc has been shown to be essential for proper recruitment of MLL and 
MLL-fusions on target loci 101. In addition, PAFc-MLL interaction has been characterized 
as essential for MLL-fusion driven leukemia 102. Conversely, the PHD fingers exert a 
negative effect on MLL-fusion mediated leukemogenesis as artificial fusions including this 
domain lost their transforming capacity 103,104.  
Second, the MLL fusion partner proteins fall into two classes: nuclear vs. cytoplasmic 
proteins (Table II). MLL-fusions to 5 nuclear proteins (AF4, AF9, ENL, AF10, ELL) cover 
over >80% of all cases of mixed lineage leukemia whereas the remaining fusion partners 
are much rare and mostly associated with adult AML.  
 
Table II. Subset of MLL fusion partners with known functions or domains. 
Name Gene alias Features Localization 
ENL* MLLT1 Binds to histone H3 assembles in ENL associated 
proteins (EAP) elongation complex 
Nuclear 
AF9 MLLT3 ENL homolog involved as well in EAP Nuclear 
AF4 AFF1, MLLT2 Founder of AF4 family, member of EAP Nuclear 
AF5 AFF4, MCEF AF4 homolog, found in EAP Nuclear 
LAF4 AFF3 AF4 homolog, found in EAP Nuclear 
ELL  Elongation factor interacting indirectly with AF4 Nuclear 
AF10 MLLT10 Associates with the disruptor of telomeric silencing H3 
methyltransferase (human: DOT1L) 
Nuclear 
CBP CREBBP Histone acetyl-transferase  Nuclear 
P300 EP300 CBP homolog Nuclear 
AF1p EPS15 Dimerization domain Cytoplasmic 
GAS7  Dimerization domain Cytoplasmic 
AF6 MLLT4 Dimerization domain Cytoplasmic 
ABI1  Associates with ENL when imported in the nucleus Cytoplasmic 
EEN  Associates with PRMT1, histone arginine 
methyltransferase, during nuclear import 
Cytoplasmic 
 
* The most frequent fusion partners are in bold police, adapted from 66.  
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The search for a common molecular mechanism underlying MLL fusion induced leukemia 
revealed that the most prevalent fusion partners and close homologs ENL and AF9 were 
both able to interact with other fusion partners such as AF4, AF5 (AF4-homolog) and 
probably AF10 105. In addition all these proteins have been purified in a complex named 
EAP (ENL associated protein) complex. This complex is able to recruit the positive 
transcription elongation factor b (pTEFb) encompassing CDK9 (cyclin-depend kinase 9) 
and a cyclin T responsible of the activation of RNA polymerase II (RNA pol II) essential for 
efficient transcriptional elongation 106,107. The actively elongating form of the RNA pol II is 
stabilized by the interaction between pTEFb and the histone acetyl interacting 
bromodomain-containing protein 4 (BRD4, member of the BET family of bromodomain 
proteins) 108,109. All together these proteins form a so-called “super elongation complex” 
(SEC). On the other hand AF9 and ENL are also components of another complex named 
“Dot.Com” including the MLL translocation partners AF10 and AF17, along with the WNT 
signaling proteins TRAPP and SKP1, and the DOT1L H3K79-methyltransferase 110. H3 
methylation on lysine 79 is also introduced during transcriptional elongation 111. Increasing 
evidence support the idea that recruitment of the EAP complex and DOT1L are essential 
for MLL-fusion protein driven leukemogenesis. Primarily, the association of ENL and AF9 
with AF4 family members seems to be crucial for maintenance of mixed lineage leukemia 
cells as the use of small peptides disrupting these interactions impaired MLL transforming 
activity 112. In the same vein, genetic studies have shown that DOT1L interaction is 
essential for transformation by the most prevalent MLL fusions and enrichment of H3K79 
methylation is required for activation of critical effectors for MLL-AF9 mediated 
leukemogenesis like Hoxa9 and Meis1 113–115. In summary, the most prevalent MLL-fusion 
partners are involved in the recruitment of a super elongation complex comprising the EAP 
interactome essential for activation and elongation of transcription, and Dot.Com complex 
maintaining the “open chromatin” state through methylation of H3K79 by DOT1L. Dual 
activation of both the EAP and the Dot.com complexes seems to result in aberrant 
transcription and activation of MLL fusion target genes. 
Interestingly, genetic studies suggested that a copy of the wildtype MLL allele is required 
for the oncogenic activity of the MLL-fusions. Indeed, it has been shown that both WT MLL 
and MLL-AF9 proteins are co-recruited on active Hoxa9 gene locus through interaction 
with MENIN 101,116. In addition, mobilization of WT MLL was necessary to induce and 
maintain MLL-AF9 mediated leukemia 116. The same group also reported that in MLL-AF9 
transformed cells, the wildtype MLL complex would be involved in transcriptional activation 
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of EZH2, the core H3K27 methyltransferase of the polycomb compex PRC2, which would 
in turn inhibit the transcription of key genes involved in proper myeloid differentiation (e.g. 
CEBPα) and therefore promote a “block in differentiation” state in the targeted cell 117. 
These observations suggest that the presence of a normal MLL allele might be a 
prerequisite for stable recruitment of the MLL-fusion on Hox genes promoters, and to 
directly regulates the transcription of other genes which are promoting leukemogenesis. 
Nevertheless how exactly the endogenous MLL and the fusion complexes cooperatively 
regulate gene expression remained mostly unclear. Interestingly, very recently it has been 
suggested that MLL-mediated hematopoietic genes expression and MLL-AF9 driven 
leukemogenesis are independent of MLL intrinsic SET domain HMT activity 118. In this 
study they show that the WT MLL target gene expression seems to be mainly dependent 
of the recruitment of MLL-associated MOF histone H4 acetyltransferase leading to H4K16 
acetylation. MOF binds directly to MLL-C, but this interaction is lost upon leukemogenic 
translocation. Here they suggest that the de novo recruitment of pTEFb and DOT1L may 
override the lack of MOF activity in the MLL-fusion context 118. 
Taken together these observations suggest that both partners of the fusion play distinct 
roles essential for leukemogenic activity: MLL on one side is involved in the binding to 
target gene promoters involved in hematopoiesis homeostasis and the most prevalent 
partner proteins are the mediators of aberrant transcriptional elongation (Fig. 8).  
 
Fig. 8: MLL-fusion macromolecular complex 
 
MLL when part of oncogenic fusion is involved imainly in proper DNA binding through interaction with MENIN 
and LEDGF/p75 a to non-methylated CpG-containing DNA islands through its CXXC domain. Interestingly 
the recruitment of transcriptional co-repressors effective in the WT MLL complex is vanished as PHD fingers 
are lost, but the proper recruitment of MLL-N on chromatin through interaction between its CXXC domain 
and PAF1 complex (PAFc) is kept. On the other end, the most prevalent partners such as AF9 or ENL are 
participating in the recruitment of a super elongation complex composed of the EAP complex which in turn 
recruits pTEFb and BRD4 both involved in RNA pol II activation and stabilization. The most prevalent MLL-
fusion partners are also known to complex with DOT1L H3K79 methyltransferase. DOT1L-mediated histone 
methylation is associated with transcriptional activation and elongation maintenance. In all, SEC and DOT1L 
are tethers to DNA by MLL-fusion, which leads to continuous transcription of MLL-target genes. 
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6. THERAPEUTIC TARGETING OF THE MLL-FUSION PROTEIN 
COMPLEX 
 
 The fact that the oncogenic activity depends on interactions of components of the 
MLL-fusion multiprotein complexes suggests novel avenues for targeted therapeutic 
strategies for MLL rearranged leukemias. Going into this direction, some reports suggest 
that the efficacy of conventional chemotherapy may be increased through additional 
inhibition of the atypical elongation and transcription exerted by the MLL-fusion complex. 
Two major strategies have been taken: to inhibit the activity or interfere with binding of the 
MLL-complex to chromatin or with recruitment of co-activators essential for the 
maintenance of the aberrant leukemogenic transcription program. 
Targeting the recruitment of the super elongation complex (SEC) 
Several attempts have been undertake to interfere with the recruitment of the SEC 
complex by MLL-fusion proteins 119. First, an AF4 peptido-mimetic “PFWT” was able to 
disrupt the EAP complex through competition with the AF4/AF9 interaction in vitro and in 
vivo 112. Treatment of MLL-AF4+ leukemic blasts with “PFWT”, although at high 
concentrations, inhibited the proliferation and induced cell death, with only minor effects on 
normal HSPCs 120. 
A second interesting approach is based on inhibition of the activity of proteins that are 
necessary to stabilize the SEC. Blocking the enzymatic activity of CDK9, a component of 
the pTEFb complex whose recruitment is crucial for maintenance of the transcriptional 
activity of the MLL fusion complex has been proposed 67,121. This strategy is promising, 
knowing the potent and apparently specific inhibitory effect of flavonoids such as 
flavopiridol, which reached the phase II of clinical trials for several hematologic and solid 
tumors 122. The main drawbacks of these compounds are their limited efficacy and high 
toxicity. Similarly, a large-scale RNA interference screen identified dependence of CDK6 
function as specific burden of MLL-rearranged AML. In this report they showed that 
pharmacologic or knockdown inhibition of CDK6 induced growth defect and differentiation 
of human and murine MLL-fusion driven cell lines in vitro and delays MLL-AF9-mediated 
disease development in vivo 123. However even if promising CDKs inhibitors are not 
selective for MLL-fusion mediated AML. In the same direction, selective targeting of the 
epigenetic reader protein BRD4 that recognizes acetylated histones participating in the 
stabilization of activated RNA pol II active form was proposed as potent anti-leukemic 
strategy 124. Several highly specific small molecule inhibitors of the BET family of BRD 
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proteins (BRD3/4) showed efficient anti-leukemic effects, however these compound are 
also active in many other forms of human cancer 124–127.  
Epigenetic targeting of the MLL fusion complex 
Several histone methyltransferases (HMTs) have been identifed as critical regulators of 
the activity of the MLL-fusion complex. Genetic studies have shown that the DOT1L 
H3K79 methyltransferase is essential for the leukemogenic activity of MLL fusion genes. 
High-resolution structure of the catalytic domain of DOT1L resulted in the development of 
a small molecule inhibitor (EPZ004777) that was able to impair MLL-fusion mediated 
leukemogenesis in vitro and in vivo 128–130. Subsequently more potent DOT1L inhibitors 
have been estabishled 131,132 and EPZ-5676, an improved version of EPZ004777 133,134, is 
currently tested in first clinical trials. 
Another attractive target might be the HMT activity on H3K4 of the wildtype MLL. Recent 
studies report the feasibility of targeting the methyltransferase activity of MLL through 
inhibition of a critical MLL-WRD5 interaction 135–137. Such efforts led to the development of 
a MLL1 selective small molecule inhibitor (MM-404) targeting MLL-WDR5 interaction that 
exclusively impaired growth, induced differentiation and apoptosis of MLL-fusion 
transformed human and murine cell lines without affecting normal mouse bone marrow 
cells 138. 
Targeting association of the MLL-complex to chromatin  
Another potential therapeutic strategy is based on interference with the binding of the MLL-
fusion complex to DNA. The first approach proposed in this regard is to target the CXXC 
CpG-containing-DNA binding domain of MLL. Indeed it has been shown that replacement 
of the MLL-AF9 CXXC domain with a lower CpG affinity CXXC domain or a methyl-CpG 
affinity domain leads to Hoxa9 silencing and abolished leukemogenic activity of the fusion 
98. Interestingly, the CXXC domain activity seems to be more crucial for the oncogenic 
activity of the MLL-fusion than for the WT MLL protein suggesting a therapeutic window for 
targeting of CXXC domain 101,139. Despite the structural resolution of the DNA non-
methylated CpG-CXXC interaction defined as drugable no small molecule selectively 
disrupting this interface has been described yet 140. 
Like interference with the CXXC domain, targeting of the MLL-MENIN-LEDGF/p75 
interactome is also promising to disrupt the binding of MLL-fusion complex to chromatin. 
Indeed, genetic studies have shown that both MENIN and LEDGF/p75 are essential 
mediators of MLL-complex recruitment on the Hox gene promoters and crucial for MLL-
ENL leukemogenic activity 99,100,141. Structural studies of the MLL-MENIN interface leads to 
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the development of small molecules inhibitors for these interaction able to affect MLL-
fusion mediated leukemogenesis 142–144. In contrast to MENIN, it is not yet clear if it would 
be feasible to target LEDGF/p75 to disrupt interaction with MENIN and/or the MLL-fusion 
to impair the oncogenic activity. 
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RESEARCH BACKGROUND AND WORKING HYPTOTHESIS 
 
My PhD project mainly focused on the functional interference with the interaction 
between MLL and LEDGF/p75 as a potential strategy for therapeutic targeting for MLL-
fusion leukemia. LEDGF/p75 has been firstly described as a DNA-binding transcriptional 
co-activator and belonging to the hepatoma-derived growth factor (HDGF) family 145.  
However other studies found weak transcriptional activity of LEDGF/p75 mainly involved in 
protection against cellular stress 146. Until know the best characterized role of LEDGF/p75 
concerns its involvement in HIV pathogenesis where it mediates tethering of the proviruses 
to the host cell chromatin through direct interaction with the HIV-integrase (HIV-IN) 147,148.  
LEDGF/p75 consists of 530 amino acids (aa) containing a N-terminal PWWP motifs 
involved in chromatin binding and a C-terminal integrase binding domain (IBD). The 
Debyser group showed that stable overexpression of the LEDGF/p75-IBD-fragment 
(aa325-530) was sufficient to disrupt the interaction between HIV-IN and LEDGF/p75 and 
inhibit HIV-1 replication 149. This study together with the structural resolution of the HIV-
IN/IBD interface 150, led to a successful rational design of small-molecule inhibitors 
disrupting the LEDGF/p75-integrase interaction to impair HIV replication 151. In the same 
vein, expression of phage-display screen derived LEDGF/p75 interacting cyclic peptides 
was able to inhibit HIV replication 152. Interestingly, LEDGF/p75 is not only a critical 
scaffold for HIV replication but seem also to play an important role in human 
leukemogenesis. First, a chromosomal translocation t(9;11)(p22;p15) associated with AML 
and blast crisis CML was found to result in a NUP98-LEDGF/p75 fusion 153,154. Second, 
high expression of LEDGF/p75 was reported in blasts from chemotherapy-resistant AML 
patients 155. Most importantly, as mentioned above, LEDGF/p75 has been shown as 
essential co-factor for the MLL-Fusions complex mediated leukemogenesis 100. ShRNA-
mediated knockdown of LEDGF/p75 expression significantly impaired the maintenance of 
MLL-ENL driven transformation in murine bone marrow. This landmark study 
demonstrated that the interaction with MENIN seems to be essential for LEDGF/p75-MLL 
complex formation, and that the oncogenic activity of MLL-ENL seems to be fully 
dependent on the PWWP domain of LEDGF/p75. Considering these findings in both HIV 
and AML pathogenesis, we initiated collaboration with the Debyser group to figure out 
whether the competition between IBD-derived fragments (or LEDGF/p75-interacting 
peptides) with the endogenous LEDGF/p75 would disrupt the MLL-MENIN-LEDGF/p75 
interface and impair MLL-fusion mediated leukemogenesis (Fig .9). 
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Fig. 9: Working hypothesis schematic representation 
 
LEDGF/p75 is known to be involved in the tethering of provirus to the host chromatin through direct 
interaction with HIV-integrase (IN) helping to its integration, an essential step for HIV viral replication. On the 
other hand, in MLL-leukemia, LEDGF/p75 together with MENIN is involved in MLL-fusion complex tethering 
to the promoter of target genes critical for leukemogenesis. Overexpression of LEDGF/p75-IBD fragment or 
LEDGF/p75 interacting peptides through competition with endogenous LEDGF/p75 abolished viral genome 
integration and impairs viral replication.  Based on this effect we proposed to use the same LEDGF/p75 
competing tools in the context of MLL-leukemia to see if we could disrupt MLL-MENIN-LEDGF/p75 critical 
interactions and in the same time impair MLL-fusion mediated transformation.   
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MATERIAL AND METHODS 
Cells 
The human leukemia cell lines: MOLM13, (AML, MLL-AF9+); THP1, (AML, MLL-AF9+); 
MV4;11 (AML, MLL-AF4+); HL-60, (AML, MLL WT); Jurkat (T-ALL); and Kasumi (AML, 
AML1-ETO+) cell lines were purchased from DSMZ (Braunschweig, Germany). All cells 
were cultured in RPMI-1640 with glutamine, supplemented with 10% fetal calf serum 
(FCS) and 1% Penicillin/streptomycin at 37°C and 5% CO2. IL3 independent murine Ba/F3 
cells expressing the FLT3-ITD mutation (Ba/F3 FLT3-ITD) have been described previously 
156. Human kidney carcinoma 293T cells (ATCC/LGC Standards, Molsheim Cedex France) 
were grown in Dulbecco's modified Eagle's medium with Glutamax (Gibco, Invitrogen, 
Merelbeke, Belgium) supplemented with 10% FCS and 1% Penicillin/Streptomycin 
(Gibco). 
Plasmids/vectors 
pMSCV (Murine Stem Cell Virus) retroviral expression vector encoding for the MLL-AF9 
fusion was provided by J. Hess (Ann Arbor) and pMSCV-MLL-ENL-neo was provided by 
Robert Slany (Erlangen). The retroviral transfer plasmid expressing eGFP (pMSCV PGK-
Puro-IRES-eGFP) was derived from pLMP (Open Biosystems, Fermentas GmbH, St Leon-
Rot, Germany) where the backbone was removed by digestion with SpeI enzyme. The 
missing part of the PGK sequence was replaced by SpeI digestion of a pMSCV-PKG-Puro 
vector (Clontech, Saint-Germain en Laye, France) and ligation of this fragment into the 
modified pLMP plasmid. To create the pMSCV plasmid expressing eGFP-LEDGF/p75325-
530 (pMSCV eGFP-LEDGF/p75325-530 PGK-Puro), eGFP-LEDGF/p75325-530 was amplified 
from peGFP-LEDGF/p75325-530-IRES-Puro using oligo’s DR1 and DR2 (Table 3) 149, 
digested with BamHI and MfeI and subcloned into pMSCV-PGK-Puro (Clontech, Saint-
Germain en Laye, France) digested by BglII and EcoRI. The shRNA- fragment for murine 
LEDGF/p75 was purchased from Open Biosystems (V2MM_34220) and subcloned from 
pSMC into the pLMP retroviral vector. The lentiviral transfer plasmids pSFFV-eGFP-I-
Puro-WS, pSFFV-eGFP-LEDGF/p75325-530-I-Puro-WS and pSFFV-eGFP–I-Puro 2xmi p75 
WS expressing eGFP, eGFP-LEDGF/p75325-530 and a duplicate LEDGF/p75 microRNA 
cassette together with eGFP respectively were made by our collaborator in Belgium as 
described previously 149,157.  
Expression vectors for various eGFP-LEDGF/p75 deletion mutants were generated by 
overlap extension polymerase chain reaction (PCR) using the LEDGF/p75325-530 subclone 
in pBlueScript-KS as template. The T3 Reverse was used as common primer to generate 
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the C-terminal deleted mutants and T7 Forward to generate the N-terminal deleted 
fragments. The smallest fragments were generated using the same strategy and using the 
two minimal active mutants identified LEDGF/p75325-386 and LEDGF/p75424-530 as 
templates. All primers used for the generation of the LEDGF/p75 fragments are described 
in Table 3. The generated LEDGF/p75 deletion mutants were then cloned back into pLMP 
expression vector.  
 
Table 3: Oligo-primers used for cloning strategies 
 Name  Sequence 5'-3' 
DR1 TTTGGATCCATGGTGAGCAAGGGCGAGGA 
DR2 GGGCAATTGCTAGTTATCTAGTGTAG 
DR3 CATATTGGATCCATGGTGAGCAAGGGCGAGGAG 
DR4 AAAGCTAGCTCAGGCACCGGGCTTG 
DR5 TTTTACTAGTACTAGCGCTACCGGACTCAG 
DR6 TTTTACTAGTCAACGCGTCCCGGTGGATCC 
DR7 AAAGGATCC ATGGGGCTGAAGGCCGCCC 
DR8 AAAAGCTAGCTCACGCGTAGTCCGGTACGTCGTACGGGTAAGCAGCAGCGA
GGCCTTTGCGCTGCCGC 
DR9 TTTTGTCGACCTCAAGCTTGCGCACAGCTGTCGGTG 
DR10 TTTTGCTAGCTTA GACTTTCTGGGGCTTTTCC 
DR11 TTTTGAATTCGGCCTGAACGATATTTTTGAAGCGCAGAAAATTGAATGGCATG
AAGTCGAC TCCCCTATACTAGGTTATTGGAAAATTAAG 
DR12 CCCCCTCGAG CTA ATCCGATTTTGGAGGATGGTC 
DR13 TTTTCATATG GCACATAGCTGTCGTTGGCG 
DR14 CCCC GGATCC TCGCACTCTGACTTCTTCATCTGAG 
DR15 GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGGGCTGAAGGCCGCCCAG 
DR16 GGGGACCACTTTGTACAAGAAAGCTGGGTCTAGAGGCCTTTGCGCTGCCGC 
410-530 For GCAGTCCAATGACTCGAGGTAATCATGGAAAAGTCTAC 
424-530 For GCAGTCCAATGACTAAGAACATGTTCTTGGTTGGTG 
450-530 For GCAGTCCAATGACTCATGAGGCGAATAAAA 
394-530 For GCAGTCCAATGACTACAGAGATGATTACTACAC 
387-530 For GCAGTCCAATGACTATGCAACAAGCTCAGAAAC 
370-530 Forw GCAGTCCAATGACTGTGAACAGATGCATTGAGG 
pBlueScript II SK T3 Rev  GGTTGGCCCTCAAAAGGG 
pBlueScript II SK T7 For TAATACGACTCACTATAGGGC 
325-499 Rev GCATCAATTGTGGTCAGTCTTCATTGCTCTCCCCGTTATG 
325-449 Rev GCATCAATTGTGGCTGTCTTTGTTCAGCAAGAGATTTATTC 
325-423 Rev GCATCAATTGTGGAAACTTGTTATACAACATTGTAG 
325-409 Rev GCATCAATTGTGGACTAACTTTGAATCGCCCTAT 
325-393 Rev GCATCAATTGTGGGTGTTTCTGAGCTTGTTGCATTG 
325-386 Rev GCATCAATTGTGTGACCTGAAGTGAAGCAAG 
345-386 For GCACTCGAGGAAACATCAATGGATTCTGCAC 
355-386 For GCACTCGAGATACATGCTGAGATTAAAAATTCAC 
366-386 For GCAGTCTCGAGGATAATCTTGATGTGAACAGATGCAAT 
375-386 For GCAGTCTCGAGGAGGCCTTGGATGAACTTGCTTCA 
424-485 Rev GCATAATTGTCATTGAGCATCAGATCCTCCATTTAG 
424-449 Rev GCATCAATTGTCACTGTCTCTTTGTTCAGCAAGAGATTTAT 
424-435 Rev GCATCAATTGTCACACGGAATCTCCTTCACCAAC 
For, forward ; Rev, reverse 
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Lentiviral and retroviral vector production 
Concentrated lentivirus was produced by our Belgium collaborators as described earlier 
158. For retroviral vector production, HEK293T cells were transiently co-transfected with 
pMSCV retroviral vectors and an ecotropic packaging vector (pIK6). The virus containing 
supernatants were collected after 48h and 72h, and only freshly harvested retroviral 
supernatants were used for retroviral infections of primary mouse bone marrow cells. 
Generation of murine MLL-fusion expressing AML cells 
Murine MLL-fusion-expressing AML cells were generated by transplantation of bone 
marrow cells retrovirally expressing the human MLL-AF9 or MLL-ENL fusions using a 
previously published protocol with some modifications 159. In brief, bone marrow cells were 
harvested from 8-weeks-old (FVB/Nx129/S1) F1 or C57/BL6 mice and enriched for 
progenitors using a lineage-marker-depletion progenitors kit (Cell Mag Kit, R&D systems, 
Minneapolis, MN, USA). These cells were cultured for 24 h in RPMI-1640 (10% FCS, 1% 
penicillin/streptomycin, 10 ng/ml of human interleukin-6 (IL-6), 6 ng/ml of murine 
interleukin-3 (IL-3) and 100 ng/ml of murine stem cell factor (mSCF)) before transduction 
with high-titer retrovirus by spinoculation (2000 g, 90 min at 33°C) on two consecutive 
days. After the second spinoculation 5x105 transduced bone marrow cells were injected 
into the tail vein of lethally irradiated (950 rad) syngeneic recipients. As described 
previously, 100% of the transplanted mice developed AML after a median latency of 86 
and 91 days for respectively MLL-ENL and MLL-AF9 fusion. 
Transduction of murine and human cells 
Murine cells were transduced using the spin infection protocol described above with 
pMSCV-PGK-Puro-IRES-eGFP-LEDGF/p75-fragments, pMSCV-LEDGF/p75-ShRNA-PGK 
-Puro or pMSCV-PGK-Puro-IRES-eGFP. Cells were flow-sorted for eGFP expression 24h 
after the second spinoculation and used as indicated for the different assays. 
Human AML cell lines were put in culture with concentrated lentiviral supernatants 
containing expression vectors pSFFV-eGFP-I-Puro-WS, pSFFV-eGFP-LEDGF/p75-
fragments-I-Puro-WS and pSFFV-eGFP–I-Puro 2xmi p75 WS (LEDGF/p75 knockdown). 
48h post-infection the eGFP+ cells were flow-sorted for eGFP and/or selected with 
puromycin as indicated.  
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Flow cytometry 
For sorting of transduced cells, the cells were washed two times with PBS, filtered and 
resuspend in FACS buffer (PBS, 0.5% BSA, 1mM EDTA) containing DAPI (Gibco, 
Invitrogen; 1/10000). eGFP-positive/DAPI negative cells were flow sorted using a BD Influx 
cell sorter (BD Biosciences Europe) into tubes containing appropriate cell culture medium. 
After sorting cells were spin down and plated according to the desire experiment set up. 
 
For immunophenotypic characterization of the murine retrovirally expressing MLL-fusion 
generated cells, frozen spleen cells isolated from MLL-AF9 mice and freshly isolated cells 
from a spleen of a FVB/NJx129 mouse were stained on ice for 30 minutes with an 
antibody cocktail containing anti- PE-CY7-C-kit PE-FcγRI/II, APC-Mac1 (eBioscience, San 
Diego, USA; 1/100) and APC-CY7-Gr1 (BD Biosciences Europe; 1/100). Subsequently the 
cells were washed and stained with DAPI (Gibco, Invitrogen; 1/10000).  
To assess the effect of LEDGF/p75-IBD fragments expression on cell differentiation, 
MOLM13 and MV4,11 human leukemic cells were transduced with pSFFV-IRES-eGFP-
LEDGF/p75-fragments or pSFFV-PGK-Puro-IRES-eGFP, and selected with 2µg/ml 
puromycin. 2x105 cells were harvested after 5, 7 and 10 days and were stained with APC-
CD11b (BD Biosciences Europe, #550019; 1 /100) and DAPI (Gibco, Invitrogen; 1/10000) 
for 15 min at RT as indicated in the manufacturer’s protocol.  
For flow-cytometric cell cycle analysis, 96 hours after transduction the cells were fixed in 
2% PFA for 10 min at room temperature, washed, permeabilized with NET gel  (150mM 
NaCL, 5mM EDTA, 50mM Tris-HCL pH7.4, 0.05% NP-40, 0.25% Lambda carrageenan 
(Sigma-Aldrich, St Louit, MO, USA)) to preserve membrane integrity and stained with 
DAPI (in PBS:0.1% Triton X-100, 1µg/ml DAPI (Gibco, Invitrogen)) for 30 min at room 
temperature. 
For flow-cytometric detection of apopotosis, the murine leukemic cells were harvested at 3, 
5, 7 and 10 days and human AML cell lines were harvested at 5, 7 and 10 days after 
puromycin selection and stained with an Annexin-V antibody (BD Biosciences Europe, 
#550475) and DAPI (Gibco, Invitrogen; 1/10000) for 15 min at RT.  
 
For all analytic flow cytometry the samples were washed with PBS after staining 
procedure, filtered and run on a Cyan ADP Flow Cytometer (Dako Cytomation, Glostrup, 
Denmark) using Summit software. Data were analyzed using Flowjo software (Tree Star 
INC., Ashland, OR, USA).  
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Clonogenic growth assays in vitro 
Colony formation was determined by plating cells in methylcellulose. MLL-fusion or WT 
mouse derived cells were plated in murine methylcellulose containing IL-3, IL-6 and mSCF 
(M3534, Stem cell technologies, Vancouver, BC) in presence of 2-4µg/ml of puromycin for 
selection of transduced cells. Ba/F3 FLT3-ITD cells as well as the human AML cells lines 
were plated in methylcellulose without cytokines (Stem Alpha.mIE, Stem Alpha, St 
Clement les Places, France) in the presence of 2µg/ml puromycin. Colonies and total cell 
numbers was counted after 5-7 days for murine cells and after 10 days for human cell 
lines.  
Giemsa cytospin-staining 
5x104 to 1x105 cells were resuspended in 100 µl PBS and spun onto glass slides using a 
Shandon Cytospin-2 Centrifuge at 350 rpm for 5 min. The slides were air dried and stained 
with Wright-Giemsa using the Hematek® Stain Pak Hematology Slide Strainer (Bayer 
HealthCare, Zurich, Switzerland). 
Growth monitoring 
In all, 2 x 104 flow-sorted eGFP-positive cells either flow sorted or puromycin pre-selected 
for 24 hours were plated in the appropriate medium under 2µg/ml puromycin continuous 
selection. Growth was monitored for 7 days by daily counting of living cells using the 
Trypan Blue dye exclusion test (Gibco, Invitrogen, Life Technologies, Paisley, UK). 
Reverse transcription quantitative PCR (RT-qPCR) 
RNA was extracted using TRIZOL® reagent (Life technologies, Grand Island, New York 
City, USA) for small amount of cells (<5x105) or the NucleoSpin® RNA kit (Macherey-
Nagel, GmbH & Co, Duren, Germany) for larger amount of cells (>5x105) according to the 
manufacturer’s protocol. cDNA synthesis was carried out with the high capacity cDNA 
reverse transcription kit (Applied Biosystems, Foster City, USA). The mRNA expression 
level was assessed in duplicate by quantitative real-time PCR using detection using SyBR 
Green for Hox-cluster genes and a TaqMan probe for the human MLL-AF9 gene fusion. 
Samples were run on an ABI prism 7700 Sequence Detection System (Applied 
Biosystems). Results were calibrated with Gapdh and calculated as ∆∆CT values 
normalized to vector control. The primer pairs used are described in Table 4. 
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Table 4: Primers used in quantitative RT-PCR analysis 
Primers for SyberGreen detection Sequence 5'-3 
mouse Hoxa7 forward GCGCAAGCTGCACATTAGT 
mouse Hoxa7 reverse CTCGGAGAGGCAAAGGGCAT 
mouse Hoxa9 forward GGTTCTCCTCCAGTTGATAGAGA 
mouse Hoxa9 reverse GAGCGAGCATGTAGCCAGTTG  
mouse Meis1 forward  CCTCTGCACTCGCATCAGTAC 
mouse Meis1 reverse CTAAGAGAGGGAAGAGGGGGTGT 
mouse Gapdh forward ATGACATCAAGAAGGTGGTG 
mouse Gapdh reverse CATACCAGGAAATGAGCTTG 
Primers for Taqman detection Sequence 5'-3 
human MLL-AF9 forward CCAGCAGATGGAGTCCACAGGATC 
human MLL-AF9 reverse GCTCTACCAGTTCATCTAGGTATGCC 
human MLL-AF9 probe AGGCTTAGGGATCCTTGAAGTGAAAAGTCCAATTAAAGC 
mouse GAPDH primers mix Mm99999915_g1, Cat Number 4331182, Life Technologies 
 
Western Blots 
Whole cell extracts of different cell lines (293T, human AML cells THP1 and the murine 
hematopoietic cell lines Ba/F3 FLT3-ITD) were made in 1% SDS, separated by 12.5% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
electroblotted onto polyvinylidene difluoride membranes (Bio-Rad, Nazareth Eke, 
Belgium). Membranes were blocked with milk powder in PBS-0.1% Tween 20, and 
detection was carried out using specific antibodies against LEDGF/p75 (Bethyl, A302-
509A), or GFP (Abcam, ab6673). Detection was performed using chemiluminescence 
(ECL+; Amersham) and horseradish peroxidase (HRP)-conjugated secondary antibodies. 
In vivo Leukemogenesis  
To address effects of LEDGF/p75-IBD derived fragments expression on MLL-fusion 
mediated in vivo leukemogenic potential, 5x104 eGFP-positive flow-sorted murine MLL-
AF9+ cells transduced with either pMSCV-IRES-eGFP-LEDGF/p75-fragments or pMSCV-
PGK-Puro-IRES-eGFP, were mixed with 106 normal total bone marrow cells from a 
healthy donor mouse and transplanted into the tail vain of lethally irradiated syngeneic 
(FVB/Nx129/S1) F1 recipient mice. Animals were sacrificed upon first signs of disease. 
 
To address in vivo effects of the combination between DOT1L (EPZ004477) and MENIN 
(MI-2-2) inhibitors on leukemogenesis, MLL-AF9 expressing murine leukemic cells were 
pretreated for 4 days in liquid culture with either control vehicle DMSO, 3µM EPZ004777, 
3µM MI-2-2, or a combination of both compounds. At day 4, 5x104 living cells were 
injected into the tail vein of sublethally irradiated C57/BL6 syngeneic recipient mice. Mice 
were sacrificed upon first signs of disease. When all the control DMSO treated mice 
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developed AML, 3 mice from each group were analyzed for histopathology to assess 
disease progression. Organs of an additional mouse from asymptomatic groups were 
analyzed at a later time point to assess development or not of the disease. Upon sacrifice 
all mice were analyzed for blood counts and organ infiltration.  All experiments were 
performed according to Swiss laws for animal welfare and approved by the Swiss 
Cantonal Veterinary Office of Basel (Switzerland). 
Statistical Analysis 
Mean values and standard deviations were calculated to estimate the degree of variation 
and GraphPad Prism 5.0 software was used for statistical analysis, as specified for each 
experiment in the figure legends. 
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RESULTS 
1. ESTABLISHING PRIMARY MLL-FUSION DRIVEN MURINE AML CELLS  
 
 In order to test the effects of functional interference with LEDGF/p75 in MLL-fusion 
driven leukemia we first established MLL-fusion induced murine AMLs. As previously 
reported, retroviral transduction of murine bone marrow (BM) cells with a retrovirus 
expressing different MLL fusions found in human patients led to leukemic transformation 
160–162. Following this strategy, we produced murine MLL-fusion gene AML by 
transplantation of lineage depleted BM cells transduced with murine stem cell virus-based 
retroviral vectors (pMSCV) encoding human MLL-ENL or MLL-AF9 leading to an acute 
leukemia phenotype after a latency period of 2-4 months (Fig. 10). Similar to earlier 
reports, the murine disease was characterized by high white blood counts, 
hepatosplenomegaly, and extensive multi-organ leukemic infiltration, reflecting clinical 
features of AML patients associated with MLL-AF9 and MLL-ENL respectively (data not 
shown) 161,163,164. To validate leukemic cells from these mice as an AML model we further 
characterized them by flow cytometry. As shown in Fig. 11A, MLL-AF9 leukemic cells 
expressed the early progenitor cell markers like C-kit and FcgRII/III as well as the myeloid 
markers Gr-1 and Mac-1. In addition, quantitative RT-PCR analysis revealed increased 
expression of known MLL target genes like the Hox-A cluster genes Hoxa9, Hoxa7 and 
Meis1 compared to control cells (Fig. 11B). These characteristics confirm previous reports 
exemplifying these MLL-fusion driven murine leukemic cells as an ideal model for the 
human disease160–164. 
 
 38 
 
Fig. 10: Generation of MLL-X leukemic primary murine cell lines 
 
(A) Schematic representation of the experimental setup. AML in mice was induced by primary transplantation 
of 5x105 lineage depleted bone marrow (BM) enriched for stem and progenitors of a donor mouse retrovirally 
expressing MLL-ENL or MLL-AF9, as a control total bone marrow of a wild-type (WT) donor was 
transplanted (BMT). Mice were killed upon the first sign of illness and BM cells were extracted to constitute 
primary MLL-ENL and MLL-AF9 expressing leukemic cells. (B) Kaplan-Meier survival analysis reveals AML 
induction in transplanted mice receiving MLL-ENL (red line) and MLL-AF9 (blue line) expressing cells 
respectively after a median latency of 83 days and 91 days whereas the mice transplanted with wild-type 
bone marrow (WT BM, black line) were still alive at the end of the experiment. 
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Fig. 11: Molecular characterization of MLL-AF9 primary leukemic cells 
 
(A) Representative FACS analysis plots of murine WT and MLL-AF9 spleen cells labeled with antibody 
against murine markers c-Kit, FcγRI/II, Gr1 and Mac1. (B) Relative amount of Mll-Af9, Hoxa9, Hoxa7 and 
Meis1 mRNA measured in murine WT and MLL-AF9 spleen cells. The expression levels were normalized to 
Gapdh and to the value of the WT control (set to 1). Error bars represent the s.d. of a triplicate quantitative 
RT-PCR analysis. 
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2. EXPRESSION OF LEDGF/P75–IBD DERIVED FRAGMENT 
(LEDGF/P75325-530) IMPAIRED SELECITVELY MLL-FUSION 
LEUKEMOGENIC ACTIVITY  
 
 Our collaborators have previously shown that expression of an eGFP (enhanced 
Green Fluorescent Protein) fused C–terminal fragment of LEDGF/p75 (eGFP-
LEDGF/p75325-530, Fig. 12A) containing the integrase binding domain (IBD) was able to 
compete with the endogenous LEDGF/p75 leading to impaired HIV-1 replication 149. To 
experimentally address whether expression of this fragment would also affect the growth 
of MLL-fusion driven leukemic cells we used the MLL-AF9 and MLL-ENL expressing cells 
isolated from the diseased mice and transduced them with pMSCV vectors expressing 
either eGFP-LEDGF/p75325-530, eGFP together with a LEDGF/p75 specific shRNA 
(“LEDGF/p75-KD”) or eGFP alone. As a control for specificity of this approach, we also 
transduced normal lineage marker-depleted mouse bone marrow cells and a murine 
hematopoietic cell line rendered IL-3 independent by expression of the human FLT3-ITD 
gene mutation (“Ba/F3 FLT3-ITD”). 48h after transduction, eGFP-positive cells were flow-
sorted and either seeded in methylcellulose to determine the effect on clonogenic growth, 
or plated in transplant medium (“TM”) to address the impact on cellular proliferation and 
expression of MLL-fusion targets. In both cases, the cells were cultured in presence of 
puromycin to select for cells carrying the virus expressing the LEDGF/p75-fragment. To 
test the effect on leukemia induction in vivo, we transplanted MLL-AF9 expressing 
leukemic cells expressing eGFP-LEDGF/p75325-530 or eGFP solely into syngeneic recipient 
mice (Fig. 12B).  
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Fig. 12: Experimental strategy set up for testing the impact of LEDGF/p75 functional 
interference in MLL-X primary leukemic cells. 
 
(A) Schematic overview of LEDGF/p75 and eGFP fused LEDGF/p75325-530. The relative positions of 
LEDGF/p75325-530, the IBD and the MLL/MENIN-binding domain are indicated. The numbers refer to amino 
acids positions of the reference sequence (GenBank accession number, NP_001121689.1). (B) Schematic 
representation of the experimental setup. Effect of the expression of eGFP-LEDGF/p75325-530 was assed on 
eGFP transduced and flow-sorted primary MLL-X leukemic cells, normal mouse lineage depleted progenitor 
cells (WT BM) and BA/F3 FLT3/ITD cells. For each cell type, clonogenic growth capacity was checked by 
colony-forming unit (CFU) assay of 104 plated cells. Hoxa9 MLL target gene expression was assessed by 
quantitative PCR (qPCR) in WT BM and MLL-X leukemic cells kept in culture 72h after sort. Effect on MLL-
fusion related AML induction in vivo was tested by secondary transplantation of 5x104 eGFP positive MLL-
AF9 murine leukemic cells together with 106 supportive total WT BM cells, into lethally irradiated syngeneic 
recipient. 
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As shown in Fig. 13A & B, expression of eGFP-LEDGF/p75325-530 significantly 
reduced the number of murine MLL-AF9 (77%) or MLL-ENL (56%) expressing colonies 
which was comparable to the effect of shRNA-mediated knockdown of LEDGF/p75 (68 
and 40%, respectively). In contrast, colony formation by normal bone marrow stem and 
progenitor cells or Ba/F3-FLT3-ITD cells was not significantly affected (Fig. 13A). 
Quantitative RT-PCR analysis revealed that expression of LEDGF/p75325-530 or shRNA-
mediated LEDGF/p75 knockdown both led to a similar and significant reduction of Hoxa9 
mRNA levels, in MLL-AF9 (47%) and MLL-ENL (34%) fusion transformed cells (Fig. 13C). 
These results indicate that overexpression of the LEDGF/p75 IBD is able to impair the 
transformed state induced by the MLL-AF9 and MLL-ENL fusions in mouse bone marrow 
cells in vitro. Upon transplantation of the transduced cell in irradiated syngenic mice we 
observed a significantly longer latency period to disease development in the group 
receiving eGFP-LEDGF/p75325-530 expressing cells (78-96 days; median 88.5 days) in 
comparison with the eGFP control group (48-78 days; median 55 days) (Fig. 13D). All 
animals ultimately succumbed to AML characterized by elevated blood counts, 
hepatosplenomegaly and multi-organ infiltration as described before (not shown). 
To strengthen these observations from the mouse model, we analyzed the effects of 
eGFP-LEDGF/p75325-530 expression in several human leukemia cell lines. Hereby we have 
selected lines with a known MLL-status, that can be efficiently virally transduced and that 
are able to form countable colonies in methylcellulose including THP-1 (AML, MLL-AF9+) 
and MOLM-13 (AML, MLL-AF9+, FLT3-ITD), and as a negative control HL-60 (AML, MLL 
WT) 162,165. Those cell lines were transduced with concentrated supernatant containing 
spleen focus-forming virus (SFFV)-based lentiviral particles expressing either eGFP-
LEDGF/p75325-530, a LEDGF/p75 specific shRNA(LEDGF/p75 KD), or eGFP alone. FACS-
sorted eGFP-positive cells were plated into methylcellulose without cytokines or kept in 
liquid medium. As shown in Fig. 14A, similar to murine AML cells, expression of eGFP-
LEDGF/p75325-530 or LEDGF/p75 knockdown significantly impaired the clonogenic growth 
of THP-1 (71% and 47% respectively) and MOLM-13 (38% and 57% respectively) without 
affecting colony formation of HL-60 cells. In addition functional LEDGF/p75 depletion, by 
either expression of LEDGF/p75325-530 or LEDGF/p75 knockdown, resulted in a growth 
defect in liquid medium as highlighted by an increase of cells in G1 phase, and a decrease 
of cells in the G2 stage of the cycle as observed in THP-1 but not in HL-60 (Fig. 14B). 
Collectively, this data shows that overexpression of the LEDGF/p75 IBD is able to impair 
the MLL-fusion induced transformed state not only in mouse but also in human leukemic 
cells in vitro.  
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Fig. 13: Expression of eGFP-LEDGF/p75325-530 selectively impairs leukemogenic activity of 
MLL fusion expressing murine AML cells in vitro and in vivo 
 
Error bars represent the s.d. of at least two independent experiments for each cell type. *, P<0.05; **, 
p<0.005; ***, p<0.001, One-way ANOVA with Tukey’s Multiple Comparison Test. (A) Colony forming units 
(CFU) per 104 eGFP flow-sorted MLL-X murine leukemic cells, normal lineage marker-depleted bone marrow 
cells (WT BM) or FLT3-ITD transformed Ba/F3 cells expressing eGFP-LEDGF/p75325-530, LEDGF/p75 shRNA 
(LEDGF/p75 KD) or eGFP/vector control (set arbitrarly as 100%).(B) Representative picture of colonies for 
murine MLL-AF9 expressing cells transduced with eGFP/vector control or eGFP-LEDGF/p75325-530. (C) 
Relative amount of Hoxa9 mRNA measured in the eGFP+ cells described in (A) by quantitative RT-PCR 72 
hours after flow-sorting. Expression levels were normalized to Gapdh and to the value of the vector control 
(set to 100%). (D) Kaplan-Meier survival analysis of syngeneic recipient mice injected with MLL-AF9+ blasts 
expressing eGFP-LEDGF/p75325-530 compared to eGFP/vector control transduced cells (* p<0.05, Log-rank 
test). 
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Fig. 14: Expression of eGFP-LEDGF/p75325-530 selectively impairs colony-forming 
capacity and cell cycle of MLL-AF9+ human AML cell lines 
 
P<0.05; **P<0.005; ***P<0.001, two-way ANOVA with Bonferroni post-tests compared with eGFP/vector 
control. (A) Colony-forming units (CFU) per 104 eGFP flow-sorted THP1, MOLM13 and HL60 cells 
transduced with eGFP-LEDGF/p75325–530, LEDGF/p75 shRNA against (LEDGF/p75 KD) or a eGFP/vector 
control (set as 100%). Error bars represent the s.d. of two independent experiments with all cell lines. A 
representative picture of colonies for each condition is shown under the corresponding histogram cell line 
serie. (B) Evaluation of the proportion of eGFP+ THP1 and HL60 cells expressing eGFP-LEDGF/p75325–530 
or a shRNA against LEDGF/p75 (LEDGF/p75 KD) vs. eGFP/vector control in the G1, S and G2 cell cycle 
stage (%). Cells were harvested 96h post-transduction. The error bars represent the s.d. of three 
independent experiments.  
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3. IDENTIFICATION OF REGIONS IN LEDGF/P75-IBD THAT ARE 
ESSENTIAL TO IMPAIR TRANSFORMED STATE 
 
 We next aimed to identify a minimal domain of LEDGF/p75325-530 that might be 
sufficient to impair the transformation potential of MLL fusions. For this purpose we applied 
PCR-based cloning to generate smaller fragments using LEDGF/p75325-530 fragment as a 
template and fused them to eGFP. As a first functional test, we assayed for the cellular 
localization of these eGFP-fused fragments by transient expression in adherent HeLa 
cells. We generated 6 C- and 6 N-terminal eGFP-fused deletion mutants covering the full-
length LEDGF/p75325-530 fragment (Fig. 15).  
 
 
Fig. 15: PCR-based generation of LEDGF/p75325-530 deleted mutants  
 
Schematic representation of the C-and N-term LEDGF/p75 deleted mutants series generated by 
polymerisation chain reaction (PCR) using LEDGF/p75325-530 fragment as a template.  
 
 
Similar to the eGFP-LEDGF/p75325-530, all C-terminal deletion mutants (LEDGF/p75325-386, 
325-393, 325-409, 325-423, 325-449 and 325-499) were localized mostly in the nucleus (Fig. 16A). In 
contrast, four of the N-terminal deletion mutants (LEDGF/p75370-530, 387-530, 394-530 and 410-
530) were excluded from the nucleus suggesting that the domain (LEDGF/p75 370-410aa) 
might play an essential role for nuclear translocation (Fig. 16B). 
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Fig. 16: Cellular localization of eGFP fused LEDGF/p75325-530 C-and N-term deleted mutants 
 
(A-B) Cellular localization of eGFP fused C-term (A) and N-term (B) deleted designed mutants serie in Hela 
cells by confocal microscopy using GFP fluorescence. Cells nuclei were stained with DAPI. The numbers 
correspond to the amino acids positions of LEDGF/p75 protein.  
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As for the entire LEDGF/p75-IBD domain, we expressed the smaller mutants in 
MLL-AF9 driven murine AML cells and determined the effects on colony formation in 
methylcellulose. We selected those deletion mutants that were able to enter the nucleus. 
The LEDGF/p75325-499, 325-393, and 325-386 C-terminal deletion mutants potently reduced 
clonogenic growth (Fig. 17A). LEDGF/p75424-530 N-terminal mutant significantly reduced 
colony growth, but no activity was observed upon expression of the N-terminal deletion 
mutants LEDGF/p75410-530 located in the cytoplasm and LEDGF/p75450-530 located in the 
nucleus (Fig. 17A). We further validated the LEDGF/p75424-530 and LEDGF/p75325-386 as 
the smallest N- and C-terminal deleted mutants significantly impairing colony growth of 
MLL-AF9 and MLL-ENL murine AML cells (Fig. 17B). Reduced colony formation was also 
associated with a significant reduction of Hoxa9 mRNA expression (Fig. 17C). These 
observations suggested that two regions of LEDGF/p75, 325-386aa (containing the very 
N-terminal part of the IBD) and 424-449aa (starting just at the C-terminal end from the 
IBD) might be critical to keep the MLL-fusion complex functional (Fig. 17D). 
 
4. NARROWING DOWN THE CRITICAL REGIONS IN THE LEDGF/P75-IBD 
TO PEPTIDE-SIZE FRAGMENTS IMPAIRING MLL-FUSION MEDIATED 
LEUKEMOGNESIS 
 
 Starting from the two regions defined above, we generated additional deletion 
mutants and expressed them in MLL-AF9 espressing murine leukemic cells (Fig. 18A). 
Hereby we were able to identify two peptide-sized fragments, LEDGF/p75424-435 and 
LEDGF/p75375-386, that both impaired colony formation (Fig. 18B). Cellular expression of 
LEDGF/p75424-530 and LEDGF/p75325-386 and of the two peptide-sized fragments, 
LEDGF/p75424-435 and LEDGF/p75375-386 was demonstrated in BA/F3 cells by western blot 
at the protein level (Fig. 18C). 
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Fig. 17: Identification of critical LEDGF/p75 regions for MLL-fusion leukemogenic activity 
 
Full-length eGFP-LEDGF/p75325-530 and eGFP/vector are used respectively as a positive and negative 
control. Error bars represent the s.d. of two independent experiments for each cell type. *, P<0.05; **, 
p<0.005; ***, p<0.001, One-way ANOVA with Tukey’s Multiple Comparison Test. (A) Colony forming units 
(CFU) per 2000-plated eGFP flow-sorted MLL-AF9 murine cells expressing the eGFP-LEDGF/p75 N-term 
and C-term deletion mutants described in Fig. 15. The error bars represent the s.d. of a duplicate 
experiment. The numbers on the X-axis correspond to LEDGF/p75 amino acids positions. (B) CFU per 104 
eGFP-flow sorted MLL-X murine leukemic cells expressing the two smallest eGFP fused N-terminal and C-
terminal active deletion mutants identified in (A) LEDGF/p75325-386 and 424-530 respectively (eGFP/vector is 
arbitrarily set at 100%). (C) Relative amount of Hoxa9 mRNA measured in cells described in (B) by 
quantitative RT-PCR 72 hours after flow-sorting. The expression levels were normalized to Gapdh and to the 
value of the eGFP/vector control (set at 1). (D) Schematic representation of LEDGF/p75325-530 indicating the 
position of the IBD, the MLL-MENIN binding site and the 2 identified critical regions for MLL-fusion 
leukemogenic activity in vitro.  
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Fig. 18: Narrowing down the minimal LEDGF/p75 domains necessary for MLL/MENIN 
interaction to active peptide-size fragments 
 
Full-length eGFP-LEDGF/p75325-530 is use as a positive control and eGFP/vector is use as a negative. (A) 
Schematic representation of the eGFP fused LEDGF/p75 mutants series derived from LEDGF/p75325-386 and 
LEDGF/p75424-530 fragments. (B) Colony forming units (CFU) per 2000 plated eGFP flow-sorted MLL-AF9+ 
murine leukemic blasts expressing the eGFP fused LEDGF/p75 deletion mutants described in (A). The error 
bars represent the s.d. of a duplicate experiment. The numbers on the X-axis correspond to the LEDGF/p75 
amino acids positions. (C) Western Blot analysis of BA/F3 cells transduced with pMSCV derived vectors 
expressing eGFP, or the indicated eGFP fused LEDGF/p75 fragments. Proteins were detected using an 
eGFP antibody. Equal loading was controlled with a α-tubuline antibody (α-Tub).  
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Expression of the small peptide-sized fragments LEDGF/p75375-386 and LEDGF/p75424-435 
reduced the clonogenic activity of MLL-AF9 and MLL-ENL murine AML cells by at least 
40% (Fig. 19A). Both fragments also significantly reduced expression of Hoxa9 in MLL-
AF9+ and MLL-ENL+ leukemic cells (Fig. 19B). In addition, expression of LEDGF/p75424-
435 and LEDGF/p75375-386 also impaired the growth of MLL-AF9+ cells in liquid culture by 3 
to 4 fold (Fig. 19C). Similarly to LEDGF/p75325-530, their expression was associated with 
altered cellular and nuclear morphology in murine MLL-AF9 cells mostly characterized by 
increased cell size with larger cytoplasm and nuclei altered chromatin structure (Fig. 20A). 
However expression of any LEDGF/p75-fragments in murine MLL fusion-driven leukemic 
cells never resulted in significant apoptosis (Fig. 20B).  
The effect of the peptide-sized LEDGF/p75 fragments was also addressed in human 
leukemic cells. Protein expression of the smaller LEDGF/p75 fragments was demonstrated 
in MLL-AF9+ human THP-1 AML cells (Fig. 21A). As observed for eGFP-LEDGF/p75325-
530, expression of eGFP-LEDGF/p75424-435 and eGFP-LEDGF/p75375-386 reduced colony 
formation of at least 40% in MLL-AF9+ THP-1 and MOLM-13 cells opposed to the HL-60 
(MLL, WT) cells (Fig. 21B). In addition, expression of eGFP-LEDGF/p75424-435 and eGFP-
LEDGF375-386 resulted in diminished cell cycle progression of THP-1 cells line but not of 
HL-60 cells (Fig. 21C). We also observed a growth defect of MV-4;11 cells (MLL-AF4+) by 
2–3 fold in liquid culture, while other acute leukemia cell lines without any known MLL-
gene alterations including JURKAT (T-ALL) or KASUMI-1 (AML1-ETO+ AML) were slightly 
or not affected (Fig. 22). However, we did not observed any significant effects of the 
peptide sized LEDGF/p75 fragments on apoptosis or on terminal differentiation of MLL-
fusion+ human cells lines. Indeed MOLM-13 and MV-4;11 human AML cells transduced 
with LEDGF/p75 fragments were not expressing at their surface increased level neither of 
phosphatidyl-serine know as an apoptotic marker detected by annexin-V binding, nor of 
CD11b macrophage differentiation marker when compared to control eGFP transduced 
cells (Fig. 23). Taken together, our data show that expression of two LEDGF/p75-derived 
eGFP-fusion peptides (LEDGF/p75424-435 and LEDGF/p75375-386) impairs the leukemogenic 
capacity of murine and human MLL-fusion expressing leukemic cells in vitro. 
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Fig. 19: LEDGF/p75375-386 and 424-435 peptide-size fragments mimic the LEDGF/p75325-530 
mediated defects in murine MLL-fusion+ AML cells 
 
Full-length eGFP-LEDGF/p75325-530 is use as a positive control and eGFP/vector is use as a negative. *, 
p<0.05; **, p<0.005; ***, p<0.001, One-way ANOVA with Tukey’s Multiple Comparison Test. Error bars 
represent the s.d. of at least two independent experiments for each cell type.  (A) CFU per 104 eGFP flow-
sorted MLL-AF9 or MLL-ENL murine leukemic cells expressing the two smallest peptide-size active deletion 
mutants LEDGF/p75375-386 and 424-435 identified in Fig. 7 (eGFP/vector is arbitrarily set at 100%). (B) Relative 
amount of Hoxa9 mRNA measured in the eGFP positive cells expressing eGFP-LEDGF/p75375-386 or 424-435 
by quantitative RT-PCR 72 hours after flow-sorting. The expression levels were normalized to Gapdh and to 
the value of the eGFP/vector control (arbitrarily set at 100%). (C) Growth curve of MLL-AF9 murine leukemic 
cells expressing the indicated eGFP-LEDGF/p75 fragments or eGFP as a control. 
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Fig. 20: LEDGF/p75 derived fragments expression is able to induce cellular and nuclear 
morphological changes but not apoptosis in murine MLL-AF9 AML cells 
 
MLL-AF9 cells transduced with the indicated eGFP fused LEDGF/p75 fragments or eGFP/vector control 
were grown in the presence of puromycin (2mg/ml) and analyzed at the indicated time points. 
(A) Representative Wright-Giemsa-stained cytospin preparation 10 days after transduction with the 
indicated. For each picture, the black scale bar in the bottom left is representative of 20 µm.  (B) Evaluation 
of the proportion of living (Annexin-V-/DAPI-), early apoptotic (Annexin-V+/DAPI-) and late apoptotic /necrotic 
(Annexin-V+/DAPI+) cell fractions by FACS analysis. 
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Fig. 21: Expression of LEDGF/p75-IBD peptide size derived fragments impairs growth of 
MLL-fusion+ human AML cell lines in vitro 
 
Full-length eGFP-LEDGF/p75325-530 and eGFP/vector are used respectively as a positive and negative 
control. *P<0.05; **P<0.005; ***P<0.001, two-way analysis of variance (ANOVA) with Bonferroni post-tests 
compared with control (eGFP). (A) Western Blot analysis of THP1 cells transduced with lentiviral vectors 
expressing the indicated eGFP fused LEDGF/p75 fragments. Fragments were detected with an eGFP 
antibody. Equal loading was controlled with an anti-tubuline antibody (α-Tub). (B) Colony-forming units 
(CFU) per 104 eGFP flow-sorted plated THP1, MOLM13 or HL60 cells expressing the indicated eGFP fused 
LEDGF/p75 fragments or eGFP/vector control (set to 100%) in the presence of puromycin. Error bars 
represent the s.d. of two independent experiments with all cell lines (C) Evaluation of the proportion of eGFP 
positive THP1 and HL60 cells expressing the indicated eGFP fused LEDGF/p75 fragments or eGFP/vector 
control in the G1, S and G2 cell cycle stage. Cells were harvested 96 hours post transduction. Error bars 
represent the s.d. of three independent experiments.  
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Fig. 22: LEDGF/p75-IBD peptide size derived fragments mediated growth defect is selective 
for MLL-fusion+ human AML cell lines in vitro 
 
Cell proliferation in liquid culture of (A) Jurkat (T-ALL), (B) Kasumi (AML1-ETO+; AML), (C) HL-60 (c-myc 
amplification; AML) and (D) MV4;11 (MLL-AF4+; AML) cells, transduced with lentiviral vectors expressing the 
indicated eGFP fused LEDGF/p75 fragments. Cells were selected with puromycin for 72 hours and plated at 
the same concentration in liquid medium at day 1 in presence of antibiotic. Error bars represent the standard 
deviation of two independent experiments. Full-length eGFP-LEDGF/p75325-530 and eGFP/vector are used 
respectively as a positive and negative control. 
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Fig. 23: Expression of eGFP-LEDGF/p75-IBD derived fragments does not increase 
apoptosis neither CD11B expression in MLL-fusion driven leukemic cell line 
 
Full-length eGFP-LEDGF/p75325-530 and eGFP/vector are used respectively as a positive and negative 
control. Cells were flow-sorted and puromycin selected after transduction, and harvested at the indicated 
days (A) Evaluation of the proportion of MOLM13 and MV4;11 cells expressing the indicated eGFP-
LEDGF/p75-fragments or eGFP as a control in living (Annexin-V-/DAPI-), early apoptotic (Annexin-V+/DAPI-) 
and late apoptotic /necrotic (Annexin-V+/DAPI+) stages. Error bars represent the standard deviation of two 
independent experiments. (B) Representative FACS analysis histogram of CD11b expression in MOLM13 
and MV4;11 cells transduced with the indicated eGFP-LEDGF/p75-fragments or eGFP/vector control. For 
each graph, the grey histogram represent unstained cells, the red line histogram eGFP/vector control and 
the blue line histogram the according eGFP fused LEDGF/p75-fragment. 
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We also investigated the effect of eGFP-LEDGF/p75375-386 and eGFP-LEDGF/p75424-435 on 
in vivo leukemogenesis using the bone marrow transplantation model (Fig. 24A). Hereby 
we observed that expression of eGFP-LEDGF/p75375-386 resulted in a moderately but 
significant prolonged latency of MLL-AF9-induced AML compared to control (median 
eGFP-LEDGF/p75375-386 = 45.5 days; median eGFP = 38 days) (Fig. 24B). Surprisingly, 
despite the potent anti-leukemogenic effect in vitro, expression of eGFP-LEDGF/p75424-435 
did not delay disease induction in vivo (median eGFP-LEDGF424-435 = 34 days; median 
eGFP = 38 days) (Fig. 24B). All animals ultimately succumbed to AML characterized by 
elevated white blood counts, hepatosplenomegaly and multi-organ infiltration (data not 
shown). 
 
Fig. 24: Expression of LEDGF/p75375-386 impairs MLL-AF9 acute leukemia in vivo 
 
(A) Schematic representation of the experimental setup. Effect on MLL-fusion related AML in vivo induction 
was tested by secondary transplantation of 504 eGFP+ MLL-AF9 murine leukemic cells expressing either 
LEDGF/p75375-386 or 424-435 eGFP fused fragments vs eGFP/vector together with 106 supportive total WT BM 
cells, into lethally irradiated syngeneic recipient. (B) Kaplan-Meier survival analysis of syngeneic recipient 
mice injected with MLL-AF9+ blasts expressing eGFP fused LEDGF/p75375-386 or LEDGF/p75424-435 
compared to eGFP/vector control transduced cells (* p<0.05, Log-rank test). 
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5. EXPRESSION OF LEDGF/P75-IBD DERIVED FRAGMENTS DISRUPTS 
MLL-MENIN-LEDGF/P75 INTERACTION 
 
 To explain the observed anti-leukemic effects of LEDGF/p75-IBD fragments, we 
hypothesized that eGFP-LEDGF/p75325-530 could compete with endogenous LEDGF/p75 
and thereby interfere with the formation of a ternary MLL/MENIN-LEDGF/p75-complex. To 
validate this idea, our collaborator Jan de Rijck, (University of Leuven, Belgium) performed 
the following co-IP experiment: he transiently co-expressed an N-terminal flag-tagged MLL 
fragment (aa 1-330, Flag-MLL1-330) comprising both the LEDGF/p75 and MENIN binding 
motifs with C-terminally HA-tagged MENIN in 293T cells (MENIN-HA). To test whether the 
LEDGF/p75325-530 fragment can outcompete LEDGF/p75 from the MLL/MENIN complex he 
then added different amounts of purified recombinant Maltose Binding Protein-tagged 
LEDGF/p75325-530 (MBP-LEDGF/p75325-530) or MBP alone in excess of endogenous 
LEDGF/p75 prior to co-IP of MLL/MENIN. While LEDGF/p75 was detected in the absence 
of MBP-LEDGF/p75325-530 or in the presence of MBP, LEDGF/p75 was either partially or 
completely displaced from the complex in the presence of 10 or 50nM of MBP-
LEDGF/p75325-530, respectively (Fig. 25A). The capacity of LEDGF/p75325-530 to displace 
LEDGF/p75 was confirmed in vitro using an AlphaScreen and purified recombinant 
proteins. Next to full length His-Thioredoxin-MENIN (H-Trx-MENIN) and Flag-LEDGF/p75, 
the N-terminal part of MLL containing the first 160 amino acids fused to Glutathione S-
Transferase (MLL1-160-GST) was purified. To analyze whether LEDGF/p75325-530 competes 
with LEDGF/p75 for MLL binding, increasing amounts of MBP-LEDGF/p75325-530 were 
added to the MLL1-160-GST/Flag-LEDGF/p75 AlphaScreen assay. As shown in Fig. 25B, 
MBP-LEDGF/p75325-530, but not MBP alone, displaced LEDGF/p75 from MLL with an 
apparent IC50 of 120.5nM (95% CI [93.9; 154.7]) confirming the data obtained by 
immunoprecipitation. Together these results strongly suggest that LEDGF/p75325-530 can 
outcompete LEDGF/p75 from the MLL/MENIN complex.  
Using an identical AlphaScreen setting our collaborators similarly analyzed whether 
LEDGF/p75424-435 and LEDGF/p75375-386 peptide-size fragments could disrupt the 
LEDGF/p75-MLL complex. For this purpose, recombinant His-Thioredoxin (HT) fused 
LEDGF/p75424-435 or LEDGF/p75375-386 fragments were purified. Both proteins inhibited the 
direct interaction between MLL and LEDGF/p75 in the AlphaScreen assay with IC50 values 
of 52.2 and 108.6nM respectively, while an unrelated control peptide was unable to disrupt 
the complex (Fig. 25C). In the same assay he also tested the activity of untagged 
peptides. While the untagged LEDGF/p75424-435 peptide did not block the MLL-LEDGF/p75 
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interaction, LEDGF/p75375-386 clearly abrogated the interaction with an IC50 of 5.8µM (Fig. 
25D). These last observations suggest the possibility that steric hindrance of the tag helps 
LEDGF/p75424-435 to disrupt the complex. Taken together, these biochemical experiments 
support the idea that LEDGF/p75-IBD-derived fragments interfere with MLL-LEDGF/p75 
through « outcompetition » of the endogenous protein from the MLL-MENIN complex. 
 
Fig. 25: LEDGF/p75-IBD derived fragments interfere with endogenous LEDGF/p75 and 
disrupt MLL-LEDGF/p75 interaction in vitro 
 
(A) 293T cells were transfected with Flag-MLL(1-330) and MENIN-HA expression constructs as indicated. 
Recombinant MBP-LEDGF/p75325-530 or MBP protein was added to the IP to compete with LEDGF/p75 from 
the complex. Flag-MLL(1-330) was immunoprecipitated using anti-Flag beads. Precipitated proteins were 
analyzed through western blot. A HA and a Flag antibody was used for detection of HA-MENIN and Flag-
MLL(1-330) respectively. Endogenous LEDGF/p75 and MBP-LEDGF/p75325-530 were detected with a 
LEDGF/p75 antibody. (B) The interaction between recombinant purified Flag-LEDGF/p75 and MLL1-160-GST 
was monitored in an Alphascreen assay upon addition of an increasing amount of MBP (Maltose binding 
protein) or MBP-LEDGF/p75325-530. Error bars indicate s.d. of triplicate measurements. One representative 
experiment out of three is shown. (C-D) The interaction between purified recombinant Flag-LEDGF/p75 and 
MLL1-160-GST was monitored in an AlphaScreen assay. Increasing amounts of His-Thioredoxin (HT) fused 
LEDGF/p75-derived peptides (C) or untagged peptides (D) were added. As a control an unrelated HT fused 
peptide (ET) was used. Error bars indicate s.d. of triplicate measurements. In each case, a representative 
titration out of three independent experiments is shown. 
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6. EXPLORING THE EFFECTS OF LEDGF/P75 INTERACTING CYCLIC 
PEPTIDES IN MLL-AF9 EXPRESSING LEUKEMIC CELLS 
 
 Based on our observation that LEDGF/p75-derived fragments competing with the 
endogenous LEDGF/p75 are able to impair MLL-fusion mediated leukemogenesis, we 
wondered whether expression of cyclic peptides known to directly interact with the 
LEDGF/p75 IBD (here called “CP63”, “CP64” and “CP65”) previously shown to be able to 
impair the cellular replication of the HIV-1 virus, would phenocpy the anti-leukemic effects 
of IBD-derived fragments 152. To abundantly express these peptides in leukemic cells, we 
cloned viral vectors encoding for N-terminal eGFP-fused CP63, CP64 or CP65. As shown 
in Fig. 26A, expression of these peptides significantly reduced colony formation of MLL-
AF9+ murine AML cells in methylcellulose over 2 rounds of consecutive plating. 
Importantly, a CP65 mutant with the potentially inactivating single W to A exchange in the 
middle of the peptide completely lost its activity in this assay. Likewise expression of the 
normal CP65 (wt) but not a W to A mutant impaired colony growth of murine MLL-AF9+ 
AML cells but did not affected colony formation of normal lineage marker-negative mouse 
bone marrow stem and progenitor cells (Fig. 26B & D). Expression of CP65 was 
associated with a significant reduction (80%) of Hoxa9 mRNA levels. The mutant peptide 
also reduced Hoxa9 mRNA expression to 60% probably due to residual binding of the 
peptide (Fig. 26C). Although at the time we performed these experiments, we did not knew 
the binding sites of these peptides on the LEDGF/p75 IBD, our observations suggested 
that these cyclic peptides might also disrupt interaction of LEDGF/p75 with MLL and/or 
MENIN impairing the transcriptional and leukemogenic activity of the MLL fusion complex.  
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Fig. 26: Expression of LEDGF/p75-IBD interacting cyclic peptides phenocopy the in vitro 
anti-leukemic effects of small LEDGF/p75-IBD fragments 
 
*P<0.05; **P<0.005; ***P<0.001, two-way analysis of variance (ANOVA) with Bonferroni post-tests 
compared with eGFP/vector control. (A) Relative Colony-forming units (CFU) per 104 eGFP-flow-sorted 
plated cells for MLL-AF9 murine leukemic blasts expressing N-term eGFP fused CP63, CP64, CP65 vs W to 
A inactive mutant form of CP65 or eGFP/vector control  (arbitrarily set at 100%) after 2 round of consecutive 
plating. The error bars represent the s.d. of a duplicate experiment. (B) Relative Colony-forming units (CFU) 
per 104 eGFP flow-sorted plated cells for MLL-AF9 murine AML blasts and murine WT Lineage negative 
bone marrow (WT BM) expressing CP65 vs its W to A inactive mutant form or eGFP/vector control 
(arbitrarily set at 100%). The error bars represent the s.d. of at two independent experiments. (C) Relative 
amount of Hoxa9 mRNA analyzed by quantitative RT-PCR after the first plating in cells described in (B). 
Expression levels are normalized to Gapdh and expressed relative to eGFP/vector control value (arbitrarily 
set at 1). Error bars represent the s.d. of two independent experiments. (D) Representative picture of 
colonies for MLL-AF9 murine AML cells described in (B).  
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7. CHARACTERIZATION OF CRITICAL INTERFACES OF THE 
LEDGF/P75-MLL-MENIN COMPLEX THAT ARE ESSENTIAL FOR MLL-
FUSION ONCOGENIC ACITIVITY 
 
 From the structural point of view, our results suggest that two protein-protein 
interfaces might be critical for stabilization of the interaction between LEDGF/p75 and 
MLL: one inside in the IBD (“interface-1”) impaired by the competing fragment 
LEDGF/p75375-386, and one at the very end of the IBD (“interface-2”) weakened by the 
LEDGF/p75424-435 competing fragment. While we were performing our experiments with the 
LEDGF/p75-derived fragments, a partial crystal structure of the MLL-LEDGF/p75-MENIN 
complex was published 166. Their work strongly suggested the existence of an interface 
composed of the α2 helix of MLL and the α4 helix of MENIN sequestrating the α5 (also αE) 
of LEDGF/p75 IBD. Interestingly the α5 helix of the IBD contains the aa 413-428 so this 
structural model somehow validated the proposed “interface-2” based on our experiments. 
Interestingly our observations suggest the existence of an MLL-LEDGF/p75 interface 
impaired by IBD interacting cyclic peptides identified as disruptors of HIV integrase-
LEDGF/p75 interface.  Based on these results our collaborators in Belgium aimed to 
characterize this potential interface in more details. They conducted intensive structural 
biochemical analysis in order to define the unstructured part of MLL involved in this 
interaction. This work led to the identification of an interface consisting in the MLL α1-α2 
helix anchored, via F148 and F151, between the two inter-helical loops of LEDGF/p75 IBD 
containing respectively aa 363, 368, 403, 406, 407 408 and aa 359, 360, 363, 399, 402, 
403 167. Interestingly they also found that part of the HIV integrase-LEDGF/p75 interface is 
sharing a strong similarity with the MLL-LEDGF/p75 interface-1. Indeed both proteins MLL 
and HIV integrase share interaction with K360, L363, I365, L368, K402, I403, F406 and 
V408 of the LEDGF/p75 IBD 150,167. These observations strongly suggest that the anti-
leukemic activity of CP65 we observed is linked to disruption of the MLL-LEDGF/p75 
complex by targeting the interface-1 we already defined by overexpression of competing 
LEDGF/p75375-386 IBD-derived fragments.  
In conclusion integrating all these findings together, our work identified two interfaces that 
seem to stabilize the MLL-LEDGF/p75 interaction, and that are critical for the transforming 
activity of most prevalent MLL-fusion genes (Fig. 27). Our work provided the fundament to 
use modern structurally guided screens for small molecules that might be able to 
phenocopy the effects of the LEDGF/p75-derived fragments and/or the LEDGF/p75 
interacting peptides. 
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Fig. 27: Dissection of MLL-LEDGF/p75 interfaces essential for MLL-fusion oncogenicity 
 
Dissection of critical LEDFD/p75 IBD interaction domains essential for MLL-fusion leukemogenic activity 
through design of LEDGF/p75-IBD derived competing peptide size fragments allowed identification of two 
MLL-LEDGF/p75 interfaces (left side of the figure). One involving LEDGF/p75-IBD, MENIN and MLL has 
been resolved in the published structure by Wang et al. (left side of the figure) and can be disrupted by the 
fragment LEDGF/p75424-435 (strong red circle on the structural scheme) leading to impaired clonogenic 
activity in MLL-AF9 expressing cells. The other one absent of the published structure has been characterized 
further and involve LEDGF/p75-IBD and MLL only (right side of the figure). The fragment LEDGF/p75375-386 
(light red circle on the structural scheme) and the LEDGF/p75 interacting cyclic peptide CP65 (blue circle on 
structural scheme) can disrupt this interaction and impair clonogenic activity of MLL-AF9 fusion. 
Cermakova et al., Can. Res., 2014 Méreau et al., Leukemia, 2013 
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8. EFFICIENT INHIBITON OF MLL-AF9 GENE DRIVEN LEUKEMIA 
MURINE LEUKEMIA BY COMBINATION OF SMALL MOLECULES 
INHIBITORS TARGETING DOT1L AND MLL-LEDGF/P75-MENIN 
COMPLEX FORMATION  
 
 Previous studies have shown that treatment of MLL-fusion gene transformed cells 
with small molecule DOT1L inhibitors leads to differentiation rather than cell death. 
However, this effect seemed rather slow and dependent of relatively high doses of the 
compound 133. Collaborators from the Novartis Institute for Biomedical Research (NIBR, 
Basel, R. Tiedt, V. Craig) therefore aimed to search for targets that are able to sensitize 
the cells to a DOT1L inhibitor (EPZ004777) by performing shRNA based knockdown 
screen focusing on epigenetic regulators in MLL-fusion positive human leukemic cell lines. 
Interestingly, MLL and LEDGF/p75 poped up as top hits suggesting that MLL complex can 
be targeted at different nodes to enhance the effects of DOT1L inhibition. Although MENIN 
was not covered in the used shRNA library, the MLL-MENIN interaction can be selectively 
interrupted by small molecule inhibitors such as MI-2-2 168,169. In absence of any available 
pharmacological agents targeting LEDGF/p75, they therefore aimed to test combinations 
of the EPZ004777 DOT1L inhibitor and the MI-2-2 MENIN inhibitor instead. Having 
different MLL-leukemia models at hand, we decided to test the combination treatment in 
our retrovirally induced MLL-AF9 AML mouse model. 
 
As a first step we assayed the compounds ex vivo in methylcellulose colony formation 
assays at two different concentrations, 3µM and 6µM in MLL-AF9+ leukemic cells and WT 
lineage depleted bone marrow progenitor cells (Fig. 28). Treatment of MLL-AF9 
expressing cells with 3µM of each compound alone led to an increase in differentiation but 
only mildly reduced colony numbers. In contrast the combination treatment significantly 
reduced their ability to form colonies in methylcellulose and significantly induced cellular 
and nuclear morphological changes associated with monocytic and granulocytic 
differentiation of the leukemic cells (Fig. 28A & B).  Likewise, a higher dose of 6µM 
EPZ004777 further reduced the colony-forming potential of MLL-AF9 expressing murine 
cells, compared to the corresponding individual compound treatments (Fig. 28A). 
Importantly, wild-type bone marrow progenitor cells did not show a substantial inhibition of 
colony formation or any significant morphological alterations at 3µM (Fig. 28C-D).  
However, the 6µM combination treatment resulted in a reduction of number of colonies in 
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methylcellulose (Fig. 28C). Considering these results, we decided to select the 
concentration of 3µM for further testing to minimize significant cytotoxic effect to WT cells.  
 
 
Fig. 28: DOT1L/MENIN inhibitors combination treatment selectively impairs clonogenic 
growth of murine MLL-AF9 expressing cells 
 
(A) Number and classification of colonies per 104 plated cells recorded after treatment of primary murine 
MLL-AF9 cells for 5 days in methylcellulose with the indicated compound concentrations. Data represent 
mean values for duplicates. (B) Representative May-Grünwald Giemsa stained cytospin preparations of the 
cells depicted in (A), Scale bar 50 µM.  (C) Colony formation per 104 plated wild type lineage depleted bone 
marrow cells after 5 days of the indicated compound treatment. Data represent mean values for duplicates ± 
s.d. (D) Representative May-Grünwald Giemsa stained cytospin preparations of the cells depicted in (C), 
Scale bar 50µM.   
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Fig. 29: Combination of DOT1L/MENIN inhibitors ex vivo pre-treatment abolished murine 
MLL-AF9 leukemic blast expansion in vivo 
 
(A) Kaplan-Meier survival analysis of secondary recipient mice injected with 5x104 MLL-AF9 leukemia cells 
that were treated ex vivo for 4 days with the indicated compound concentrations. Percent of disease-free 
animals upon sacrifice are represented. (B) Representative hematoxylin and eosin-stained bone marrow 
sections for each treatment group. Analysis was performed after all DMSO control animals showed signs of 
disease, scale bar 100µM. (C) Hematoxylin and eosin–stained bone marrow sections from an asymptomatic 
recipient mouse injected with EPZ00477 or combination treated cells taken at a later time point (55 days) to 
assess disease development/progression, scale bar 100µM. (D-E) Spleen size measurements (D) and white 
blood cell (WBC) counts (E) for all animals involved in the study. 
 
To address the potential synergy of the compounds in vivo, we ex vivo pretreated MLL-
AF9 expressing murine leukemic cells for 4 days in liquid with either control vehicle 
DMSO, or 3µM of EPZ004777, MI-2-2, or combination of both compounds. A pretreatment 
schedule is necessary as both compounds have a very short half-life in vivo, and we have 
no possibility to use intravenous pumps in mice. At day 4, 5x104 living cells were injected 
into the tail vein of sublethally irradiated C57/BL6 syngeneic recipient mice. Mice were 
sacrificed upon first signs of disease. When all the control mice (DMSO treated cells) 
developed AML, 3 mice from each group were analyzed for progression of the disease by 
histopathology. All mice transplanted with control cells (n=8) or MI-2-2 treated cells (n=6) 
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developed the classic MLL-AF9 induced AML after short latency (Fig. 29A). Leukemia 
formed also in 3 out of 8 mice transplanted with EPZ004777 pretreated cells. In contrast, 
none of the mice transplanted with cell pretreated with the combination (n=8) developed 
any symptoms of disease (Fig. 29A). Histopathology revealed that bone marrow integrity 
was preserved in all mice that received the cells pretreated with the combination (Fig. 
29B). They also presented white blood cells and spleen size in a normal range (Fig. 29D-
E). One asymptomatic mouse from the EPZ00477 and from the combination group was 
analyzed for histopathology at a later time point (day 55 post-transplant) to assess 
potential disease progression but no signs for progression was found with normal bone 
marrow in both animals (Fig. 29C). Except the mice transplanted with the combination, all 
symptomatic mice showed excessive multi-organ infiltration of leukemic cells (Fig. 30A). In 
contrast, no clear blast infiltration was observed in the asymptomatic mice even when 
analyzed at a later time point, except a unique suspicious spot in the liver of a mouse 
injected with EPZ004777 treated cells (Fig. 30B). The experiment was terminated when 
the remaining animals in the EPZ004777 and combination group reached 3 times the 
latency that was observed for disease development of the control (DMSO-treatment) 
group (25 days). Further characterization of the pre-treatment setting indicated that single 
or combination treatment of MLL-AF9 expressing cells ex vivo did not significantly 
impaired their growth or viability (Fig. 30C-D). However we observed significant 
morphological signs of differentiation, such as lighter cytoplasm with granulation and donut 
shape nucleus, particularly after combination treatment (Fig. 30E). This data suggested 
that transient and non-lethal exposure of leukemic cells to the combination treatment is 
sufficient to permanently disable their leukemogenic infiltration potential. Altogether, these 
results demonstrate that the combination of EPZ004777/MI-2-2 has synergistic and 
durable anti-leukemia effects in an MLL-AF9 driven AML mouse model. 
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Fig. 30: DOT1L/MENIN inhibitors combination ex vivo pre-treatment induces non-lethal 
differentiation of MLL-AF9 leukemic blasts abolishing leukemogenic infiltration in vivo. 
 
(A-B) Hematoxylin and eosin–stained organs sections from (A) mice analyzed when all the DMSO control 
mice came with disease and (B) an asymptomatic recipient mouse injected with EPZ00477 or combination 
treated cells taken at a later time point (55 days) to assess disease development/progression, scale bar 
100µM. (C-D) Growth curve analysis (C) and percentage of trypan blue counted dead cells (D) recorded for 
MLL-AF9 cells after 4 days of treatment. (E) Representative May-Grünwald Giemsa stained cytospins of 
murine MLL-AF9 cells after 4 days of treatment in liquid culture with DMSO, 3µM EPZ004777, 3µM MI-2-2 
and combination, scale bar 100µM. 
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DISCUSSION 
 
 MLL-fusion gene expressing acute leukemia represents a genetically and clinically 
distinct subset of leukemic disorders that are often associated with a poor prognosis and a 
high relapse frequency. The availability of reliable human and mouse models for MLL-
fusion driven leukemia as well as intensive biochemical and structural studies boosted the 
research for the development of targeted therapeutic strategies. There is increasing 
evidence that normal MLL as well as MLL-fusion act in the form of dynamically-assembled 
high molecular complexes whose association is essential for MLL-mediated normal and 
leukemic hematopoiesis 66,67,110. Recently genetic and structural studies suggested that 
interactions between LEDGF/p75, MENIN and MLL could offer interfaces for potential 
therapeutic targeting 100,170,171 The interaction between MLL and MENIN has been 
structurally characterized and small molecules targeting this interface have been identified 
142,166,169,170. These compounds bind to a central hydrophobic pocket of MENIN and 
thereby destabilize the LEDGF/p75-MLL-MENIN ternary complex. The small molecule 
MENIN inhibitor (MI-2-2) was demonstrated to specifically induce cell growth arrest and 
differentiation in leukemia cells with MLL-fusions 166,168. However MENIN is also a known 
tumor suppressor in endocrine tissues suggested to be linked to its interaction with the 
JUN-D protooncogene 172. Structural data suggested that the interaction of JUN-D with 
MENIN is highly similar to the MENIN-MLL interaction suggesting possible cytotoxic 
effects of MENIN inhibition in other contexts (e.g. MEN-syndrome) than solely MLL-
rearranged leukemia. Very recent studies have shown that expression of some MLL-
regulated genes might not be dependent on MENIN suggesting a LEDGF/p75-MENIN 
independent chromatin interaction mechanism 173. In correlation it is known that MLL 
interacts directly with non-methylated CpG through its CXXC domain whose targeting has 
also been suggested as a potential therapeutic strategy for MLL-rearranged leukemia 
98,139,140. MLL has been shown to be a major regulator of transcription in mammalian cells 
influencing approximately a third of all expressed genes in a context-dependent manner 
174. MLL is essential for maintenance of adult hematopoietic stem cells but also important 
for formation and function of other organs 75,76,175. Therefore, as targeting of the MENIN-
LEDGF/p75-MLL interface might also affect the function of WT non-rearranged MLL in 
hematopoietic and non-hematopoietic tissues, the strategies need to be carefully 
evaluated for a beneficial therapeutic window between normal and malignant cells. 
  
 69 
Our work aimed to functionally explore interference with MLL-MENIN-LEDGF/p75 complex 
as a strategy for targeted therapy of MLL-fusion leukemia. Previous studies have 
characterized LEDGF/p75 as a key host-cell co-factor during HIV-1 replication by tethering 
the viral pre-integration complex to active chromatin 176. In addition, both, the MLL-MENIN 
and the HIV pre-integration complex was shown to interact with LEDGF/p75 through the 
so-called integrase binding domain (IBD) 100,150. Interestingly, expression of an eGFP-
fused LEDGF/p75 C-terminal fragment (eGFP-LEDGF/p75325-530) encompassing the IBD 
and the MLL/MENIN interaction domain, was able to selectively impair HIV-1 replication 
through competition with endogenous LEDGFp75 148,149. These observations led us to 
explore this strategy for targeted interference with MLL fusion-mediated leukemogenesis 
(Fig. 9). Expression of eGFP-LEDGF/p75325-530 selectively impaired clonogenic growth of 
MLL-fusion expressing human and murine AML cell lines (Figs. 13 & 14). Decreased self-
renewal capacity upon functional interference with LEDGF/p75 was associated with 
downregulation of Hoxa9 and general growth defect in murine MLL-fusion transformed 
cells (Fig. 13). Through structural-functional analysis of the LEDGF/p75-IBD, we were able 
to depicted two peptide-size-IBD derived fragments able to phenocopy the “anti-leukemic” 
effects of the full-length LEDGF/p75325-530 in MLL-fusion expressing cells (Figs. 15-19 & 
21). Interestingly, the two identified peptide size fragments LEDGF/p75375-386 and 
LEDGF/p75424-435 are located on either side of the IBD indicating the existence of two 
distinct MLL-interaction sites on LEDGF/p75 150 (Figs. 17C & 18).  
 
Based on the recently published partial structure of the MLL-MENIN-LEDGF/p75 complex 
the LEDGF/p75424-435 peptide directly targets a critical interface between the αE helix of 
the LEDGF/p75 IBD, α4 of MENIN and α2 of MLL, explaining its inhibitory effect 166 (Fig. 
27). The contacts of the LEDGF/p75375-386 peptide with the MLL-MENIN complex were 
however not resolved in the published crystal structure. However, our collaborators have 
structurally and biochemically shown that a direct interaction exists between MLL and 
LEDGF/p75 in the absence of MENIN 177. This is at odds with the co-IP data presented in 
our paper and in previous work that suggested MENIN to be required for the interaction 
100,177. It is possible that co-IP experiments might be not sensitive enough to detect the 
interaction or that the interaction is modulated by posttranslational modifications. However, 
their results strongly support the existence of another interaction site for MLL in the 
LEDGF/p75 IBD that can be disrupted through overexpression of the fragment 
LEDGF/p75375-386.  
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Based on this work our collaborators (J. De Rijck et al., KU Leuven) went further on the 
characterization of the MLL-LEDGF/p75 interface and managed to depict another direct 
interaction. This interface involves MLL helixes α1- α2 anchored via F148 and F151 
between two LEDGF/p75 IBD inter-helical loops and forming targetable hydrophobic 
pockets 167 (Fig. 27). In more details MLL F148 occupies a hydrophobic pocket on the 
LEDGF/p75-IBD surface formed by L363, L368, I403, F406, K407 and V408, while MLL 
F151 is buried on a pocked formed by the LEDGF/p75-IBD amino acid residues I359, 
K360, L363, T399, K402 and I403. Interestingly this interaction seemed to be independent 
of MENIN recruitment showing the potency of targeting selectively MLL-LEDGF/p75 
interaction without interfering with MENIN. In addition, there seems to be a partial but not 
integral overlap between the LEDGF/p75-MLL and LEDGF/p75–HIV integrase interfaces. 
In this regard, we showed that overexpression of LEDGF/p75 IBD interacting cyclic 
peptides known to disrupt HIV-Intergrase interaction were also able to impair the 
clonogenic potential and Hoxa9 expression of murine MLL-AF9 expressing bone marrow 
cells 152,167 (Figs. 26 & 27). Collectively, these results suggested two distinct potential 
druggable interfaces in the LEDGF/p75-MENIN-MLL complex and one of them seems to 
be not only essential for the leukemic activity but also for HIV-replication. Therefore 
currently ongoing studies now aim to develop small molecules that are able to imitate the 
activities of the peptides used for defining the critical interfaces. A similar strategy led to a 
novel class of small molecules that target the HIV-integrase that are currently tested in 
clinical trials 151. 
 
Previous studies demonstrated that small molecules inhibitors targeting the MLL-MENIN 
interaction or the DOT1L histone methyltransferase associated with the MLL-fusions 
results in differentiation and apoptosis of MLL fusion gene-driven leukemic cells 
124,126,133,169,178. However, despite a significant defect on growth and self-renewal of MLL-
fusion expressing cells, we did not observe any significant induction of apoptosis or 
differentiation upon expression of the LEDGF/p75 fragments (Figs. 20 & 23). This 
controversial observation might result from the retroviral expression approach we used.  
Indeed we showed that MLL-fusion protein is very highly expressed in leukemic cells 
extracted from a retrovirally MLL-AF9 diseased AML mouse (Fig. 11). Therefore, it is likely 
that by using a competition approach through retroviral expression of the LEDGF/p75 
fragments, we were not able to reach enough expression to totally outcompete the MLL-
fusion complex necessary to induce terminal differentiation and apoptosis. Nevertheless 
using this strategy, we were able to show that expression of the eGFP-LEDGF/p75325-530 
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or eGFP-LEDGF/p75375-386 fragments moderately delayed leukemia induction in a mouse 
bone marrow transplantation model. Our collaborators (KU Leuven) further proved that 
LEDGF/p75325-530 disrupts the MLL/MENIN-LEDGF/p75 complex in co-IP experiments and 
an AlphaScreen protein-protein interaction assays (Fig. 25). These results are in 
agreement with the hypothesis that LEDGF/p75325-530 competes with endogenous 
LEDGF/p75. Importantly, like LEDGF/p75325-530, the tagged peptide fragments disrupted 
the LEDGF/p75-MLL complex in a dose-dependent manner (Fig. 25). Surprisingly, the 
untagged LEDGF/p75375-386 peptide inhibited the MLL-LEDGF/p75 interaction, whereas 
the LEDGF/p75424-435 peptide did not (Fig. 25). Possibly, steric hindrance of the tag helps 
LEDGF/p75424-435 to disrupt the complex.  
 
Structural functional studies also suggested that LEDGF/p75 might be able to thether the 
MLL-complex to its target genes like the HOX cluster by its PWWP chromatin-binding 
domain but independent of the MENIN interaction 100,179. Importantly replacement of the 
LEDGF/p75-MENIN binding domain by the PWWP domain of LEDGF/p75 was sufficient to 
rescue leukemic transformation activity of MLL-fusion in the absence of MENIN 100. Very 
recently the same researchers suggested that only the CXXC domain of MLL and the 
PWWP domain of LEDGF/p75 were essential for DNA binding to target promoter genes 
and for transforming capacity of the MLL-ENL fusion in vitro and in vivo 179. Based on 
these results and to strengthen the specificity of our IBD-interfering strategies for MLL-
LEDGF/p75 interfaces, we engineered a mutated MLL-AF9 fusion containing the PWWP 
domain of LEDGF/p75 but lacking the putative MENIN-LEDGF/p75-interaction site. Briefly, 
the PWWP domain of LEDGF/p75 was fused to MLL-AF9 whereas the MENIN binding 
sites were removed and a MLL F129A abrogating point mutation of the LEDGF/p75 
binding domain was inserted. However, in several attempts, we were not able to obtain 
stable transformation by retroviral expression of this MLL-AF9 mutant in mouse bone 
marrow cells in vitro or leukemia induction in vivo (data not shown). This observation goes 
along with our finding that the F129A mutation was not sufficient to totally abrogate 
LEDGF/p75-MLL interaction 177. In addition, according to the structure established by our 
collaborators, addition of MENIN in the MLL-LEDGFp75 in vitro interaction assay induces 
a 4-fold stimulation of the interaction 167. These observations suggest that that, the 
PWWP-F129A MLL-AF9 is not able to form a stable MLL-LEDGF/p75-MENIN interaction 
essential for malignant transformation of the cells. 
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Importantly, we observed that expression of the eGFP-LEDGF/p75325-530 or LEDGF/p75 
IBD-interacting cyclic peptide (CP65-eGFP) had strong anti-leukemic activity but did not 
impair normal bone marrow stem and progenitor cells (Figs. 13 & 26) suggesting a 
possible therapeutic window between normal and leukemic cells through functional 
inhibition of LEDGF/p75-MLL interactions. In addition, according to our results functional 
interference with LEDGF/p75 through overexpression of the IBD-derived fragment seemed 
to be rather selective for MLL-rearranged leukemic cells, as murine BAF3 cells 
immortalized by overexpression of a constitutively active kinase (FLT3-ITD) or other 
human AML cells without MLL-fusion (e.g. HL60, JURKAT, KASUMI) were not affected 
(Figs. 13, 14, 21 & 22). Therapeutic interference with the MLL-LEDGF/p75-MENIN 
interactions represents an indeed targeted and rather specific approach unlike other 
strategies that interfere with other, more functionally associated mediators of the MLL-
complex such as BRD4, PAFc or pTEFb that are more general effectors of transcription, 
and despite the efficient anti-leukemic effects, are associated with significant toxicity 
122,180,181. 
 
Advances in understanding of MLL fusion leukemia have led to the identification of several 
potential therapeutic strategies. Currently, inhibition of H3K79me DOT1L histone 
methyltransferase associated with the MLL-fusion complex is the most clinically advanced 
concept. Recently developed small molecule inhibitors of DOT1L, such as EPZ004777, 
SGC0946, and EPZ-5676, have been shown to efficiently block H3K79 methylation, inhibit 
expression of MLL fusion target genes and selectively kill cells with MLL 
translocations178,182,183. However, DOT1L inhibitors seem to act slowly and inefficiently in 
many MLL-rearranged cell lines and only xenografts of a particularly sensitive human cell 
line (MV4;11) have successfully been treated in vivo 178,182. Nonetheless, EPZ-5676 has 
been recently promoted into phase 1 clinical studies as a targeted therapy for patients with 
MLL-rearranged leukemias and represents the first reported histone methyltransferase 
inhibitor to enter human clinical trials. In this context our collaborator at Novartis (R. Tiedt 
and V. Craig, NIBR Oncology, Basel) aimed to identify synergistic modulators of DOT1L 
inhibition. Using a deep coverage shRNA screening platform (“DECODER”)184 they 
identified several candidate sensitizer genes whose depletion strengthens the action of 
DOT1L inhibition in human AML cells harboring MLL fusions. Notably, they observed a 
strong enrichment for genes that are implicated in the MLL complex including MLL and 
LEDGF/p75. In absence of any available pharmacological active agents that are able to 
target LEDGF/p75, they set out to test the EPZ004777 DOT1L inhibitor in combination 
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with the MENIN inhibitor MI-2-2 targeting the MLL-MENIN-LEDGF/p75 interaction 168,169. 
Therefore, we focused on characterizing between potential synergisms between DOT1L 
and MENIN inhibition as a robust therapeutic strategy using our MLL-AF9 AML mouse 
model. Hereby we observed a strong decrease of self-renewal capacity in vitro CFU assay 
upon combination treatment of murine MLL-AF9 expressing cells, which was not the case 
when the cells were exposed only to the DOT1L or the MENIN inhibitor (Fig. 28). Second, 
we found a complete lack of AML formation in vivo after transplantation of ex vivo pre-
treated MLL-AF9 cells for only 4 days provides strong evidence that short exposure to the 
combination treatment is sufficient to initiate an irreversible differentiation that efficiently 
abrogate leukemia initiation (Figs. 29 & 30). In contrast, we found no dramatic effect of the 
combination treatment on the clonogenic growth of normal bone marrow hematopoietic 
stem and progenitor cells (Fig. 28). Our collaborators from Novartis also tested the 
DOT1L/MENIN inhibitor combination on a subset of human non MLL-rearranged leukemic 
cells (K562, a chronic myelogenous leukemia cell line and two B-ALL cell lines, REH and 
NALM6) and observed only very limited effects on proliferation and viability in vitro. 
Similarly no significant effect of the combination was observed on clonogenic growth of 
human peripheral blood derived CD34+ progenitors (data not shown). All together, these 
results suggest therapeutic selectivity of the DOT1L/MENIN inhibitor combination for MLL-
rearranged leukemia. Eventually this combination might help to reduce the potential 
development of resistance towards enzymatic inhibitor. Several examples highlight the 
success of combining targeted agents in clinical trials as a means to overcome the rapid 
onset of resistance to monotherapy. For instance, combining BRAF and MEK inhibitors 
has been shown to effectively treat Melanoma patients with BRAF V600 mutations 185. 
Similarly BRAF V600E mutant colon cancers have been shown to benefit from 
combination therapy consisting of BRAF and EGFR inhibitors 186,187. Both examples 
emphasize that targeting the same pathway at two different nodes results in a superior 
outcome. Evidently, the large number of possible combinations of targeted agents that 
could be considered for treatment remains a challenge. These results therefore highlight 
the power by which RNAi sensitizer screens utilizing high coverage shRNA libraries can be 
translated into enhanced therapeutic strategies. Following similar objectives, Klaus et al. 
recently reported that the DOT1L inhibitor EPZ-5676 displayed strong synergy with 
standard of care chemotherapies and DNA hypomethylating drugs in MLL-rearranged 
leukemia cells 188. Likewise, Liu et al. demonstrated that treatment with an alternative 
DOT1L inhibitor significantly increased the sensitivity of MLL-rearranged leukemia cells to 
chemotherapeutics 189. However, as of yet, no targeted therapeutic partners for DOT1L 
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inhibition have been proposed. In this regard, our study ultimately provides a rationale for 
combining DOT1L and MENIN inhibitors in MLL patients, which typically have a very poor 
clinical outcome. 
 
Interestingly, the DECODER screening led by Novartis on MLL-fusion cells highlighted 
additional MLL related factors (e.g. WDR5 and BRD4) as potential therapeutic 
combination partners with DOTIL inhibitors. Several studies suggested that the normal 
non-rearranged wildtype MLL protein might play a critical role in MLL-driven 
leukemogenesis 116. Going along with these studies, there is this observation that leukemic 
blasts with MLL rearrangements normally maintain a normal copy of the gene. In addition, 
some AML cases have been reported harboring amplifications of the MLL genes 
furthermore suggesting that the activity of un-rearranged protein can contribute to a 
malignant phenotype 190,191. Indeed, recent studies suggest that targeting WDR5 an 
essential co-factor for the MLL-mediated histone methyltransferase activity by small 
molecule inhibitors or genetic knockdown impairs the leukemogenic activity of MLL fusion 
genes 135–138. Interestingly WDR5 has been previously shown to act as adapter between 
the MLL histone methyltransferase and the MOF acetyltransferase, that seem to act 
closely together to allow proper activation of critical target genes 192. Very recent work 
suggested that the transcriptional program directed by the MLL complex is mainly relies on 
MOF-mediated H4K16 acetylation 118. Some MLL fusions involve histone acetyltransferase 
(HAT) such as CBP and p300 strengthen the potential of targeting the associated HAT 
activity in acute leukemia 83,84. Interestingly the CBP/p300 co-activator complex has been 
newly shown to be critical for MLL-fusion but also for AML1-ETO driven leukemogenesis in 
the mouse 193. CBP/p300 seem not only to modify chromatin of critical downstream targets 
but also affect the activity of oncogenic fusion proteins by direct acetylation 193. 
Interestingly, acetylated lysine-residues of activated chromatin are recognized by 
bromodomains (BRDs). Bromodomains are understood as “epigenetic reader” protein 
interaction modules. Structural characterization of the BRDs interaction resulted in the 
discovery of potent and highly specific inhibitors of the BET (Bromodomain and Extra-
Terminal) protein family 180. Blocking of the BRD4 BET protein severely impairs 
transcriptional activation, particularly of the so-called “super-enhancers” that are critical 
regulators of key oncogenes like c-myc 194,195. Multiple studies have demonstrated anti-
cancer activity of small molecule BET-family inhibitors resulting in potently reduced 
proliferation and survival of MLL-fusion driven leukemic blasts 124,126,127. Overall 61 BRDs 
have been found in 46 human proteins including many transcriptional co-regulators and 
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chromatin-modifying enzymes that are involved in the pathogenesis of AML suggesting 
additional opportunities for therapeutic targeting. Interestingly, the CBP/p300 HATs seem 
to recognize acetylated chromatin through their BRD, and both the HAT and the BRD 
seem to be crucial for MLL-CBP mediated leukemogenesis 196. This observation suggests 
a possible synergistic “anti-leukemic” effect by combining HAT and BRD domain inhibition 
of CBP. A major advantage of this combination would be to modulate the dose of potential 
compounds to avoid unselective cytotoxic effects linked with either BRD or HAT targeting. 
Although there are currently no clinically relevant selective inhibitors that target HAT, in 
collaboration with the Structural Genomic Consortium (SGC, S. Knapp and co-workers) 
our laboratory has recently characterized a potent anti-leukemic activity of a novel small 
molecule that selectively targets the BRD of CBP/p300. Interestingly, this compound 
seems to primarily affect self-renewal of leukemic cells without significant cytotoxicity. 
Importantly, this compound seems to act synergistically with BET family BRD inhibitor 
(Picaud et al., submitted). Previous studies have shown that, although not really selective, 
histone deacetylase inhibitors (HDACi) have potent “anti-leukemic” activity in acute 
leukemia197. This effect was mainly associated to the release of fusion gene directed 
transcriptional silencing of genes that are normally regulating differentiation and apoptosis. 
However, HDACIs treatment applied to AML patients seem to have modest activity even in 
combination with the conventional chemotherapy and limited by progressive constitutional 
symptoms 198. In this context, it would also be an interesting option to address the potential 
synergistic effects between HDAC and BRD inhibitors.  
 
MLL fusion gene driven acute leukemia represent a clinical challenge. The experimental 
work of my PhD project helped to define critical protein-protein interactions particularly of 
LEDGF/p75 to MLL and MENIN that are essential for the leukemogenic activity of MLL 
fusion proteins. Most importantly, our structure functional studies revealed a MENIN-
independent LEDGF/p75-MLL interface that is currently followed for design of small 
molecules selectively targeting this interaction. In addition, we were able to demonstrate 
strong synergism between DOT1L and MENIN-MLL interaction inhibitors in the context of 
most common MLL-fusion leukemia. We are convinced that such strategies will be 
necessary to overcome early resistance and relapse leading to an improved outcome for 
patients suffering from MLL-rearranged leukemia. 
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